Document:

License Agreement

 Exhibit 10.17 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 

LICENSE AGREEMENT 
 This License Agreement, effective upon the date of last signature herein (the “Effective Date”), by and between The Penn State Research Foundation (hereinafter referred to as “PSRF”),
a non-profit corporation duly organized and existing under the laws of the Commonwealth of Pennsylvania and having an office at 304 Old Main, University Park, PA 16802, and Genomatica, Inc., a corporation organized under the laws of the State of
California (hereinafter referred to as “LICENSEE”), having its principal office at 5405 Morehouse Drive, Suite 210, San Diego, CA 92121. 
 WITNESSETH 
 WHEREAS, [...***...], employees of The Pennsylvania
State University (the “UNIVERSITY”) have made an invention entitled “[...***...]”, filed as The Pennsylvania State University Invention Disclosure No. [...***...] (the “INVENTION”); 

WHEREAS, PSRF is dedicated to fostering and advancing scientific research within the Commonwealth of Pennsylvania and, in particular,
within the UNIVERSITY and is responsible for developing inventions made by employees of the UNIVERSITY by evaluating invention disclosures, pursuing patents, and pursuing licensing arrangements thereon; 

WHEREAS, PSRF is the owner of certain “PATENT RIGHTS” (as defined hereinbelow) relating to INVENTION and has the right to grant
licenses under PATENT RIGHTS; 
 NOW THEREFORE, in consideration of the mutual promises and covenants set forth herein and for
good and valuable consideration, the adequacy and sufficiency of which is hereby acknowledged, the parties hereby agree as follows: 
 ARTICLE 1 
 DEFINITIONS 

For purposes of this License Agreement, the following words and phrases shall have the following meanings: 

1.1 “AFFILIATES” shall mean any entity which directly or indirectly controls, is controlled by or is under common
control with Licensee. The term “control” as used herein means the possession of the power to direct or cause the direction of the management and the policies of an entity, whether through the ownership of a majority of the outstanding
voting securities or by contract or otherwise. 
 1.2 “LICENSEE” shall be Genomatica, Inc. and its Affiliates.

  

					
		 	1.	  	***Confidential Treatment Requested

 1.3 “FIELD” shall mean the study and determination of optimal performance
characteristics of biochemical reaction and regulatory networks, including, [...***...]. 
 1.4
“TERRITORY” shall mean the world. 
 1.5 “PATENT RIGHTS” shall mean all of the following without
limitation: 
 (a) U.S. Provisional Patent Application No. [...***...], filed on [...***...], together with
all pending and issued U. S. and foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations,
continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and prosecuted pursuant to
Article 6 and; 
 (b) U.S. Provisional Patent Application No. [...***...], filed on [...***...], together
with all pending and issued U. S. and foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations,
continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and prosecuted pursuant to
Article 6. 
 1.6 “LICENSED PRODUCT” shall mean any process, product or part thereof, or use or manufacture of
a product or part thereof, which is covered in whole or in part by at least one unexpired claim of PATENT RIGHTS in the country in which any such process, product or part thereof is made, used, or sold. 

ARTICLE 2 

THE LICENSE 
 2.1 Subject to any preexisting rights, if any, of the Government of the United States created by the use of Government funding, PSRF hereby grants to LICENSEE an exclusive right and license in the
TERRITORY for the FIELD, with right to sublicense, to PATENTS RIGHTS and, to the extent not prohibited by other third party patents, to make, have made, use, lease, sell, have sold, offer for sale, and import LICENSED PRODUCTS for the term set forth
herein, unless this License Agreement shall be earlier terminated according to the terms and conditions contained herein. 

2.2 PSRF reserves the rights for itself and the UNIVERSITY [...***...]. 

2.3 LICENSEE agrees that LICENSED PRODUCTs leased or sold in the United States will be manufactured substantially in the United
States. 

  

					
		 	2.	  	***Confidential Treatment Requested

 2.4 LICENSEE shall have the exclusive right, at its sole discretion, to sublicense
any of the rights, privileges and license granted hereunder during the term of this License Agreement. 
 2.5 The license
rights granted hereunder shall not be construed to confer any rights upon LICENSEE by implication, estoppel or otherwise to any technology owned or controlled by PSRF which is not specifically set forth herein. 

2.6 UNIVERSITY hereby grants to LICENSEE an exclusive option to acquire an exclusive, worldwide license (with the right to
sublicense) to develop, make, have made, use, sell, have sold, offer for sale and import products and employ methods covered by or incorporating any [...***...] invention in the FIELD discovered or reduced to practice by [...***...]
during the term of this Agreement (each, a “[...***...] Invention”). UNIVERSITY shall promptly notify LICENSEE in writing of any such [...***...] Invention. With respect to any specific [...***...] Invention, such option
shall extend for a period of [...***...] following the date of [...***...] in writing to LICENSEE by UNIVERSITY of [...***...] (the “Option Term”). The Option Term with respect to any particular [...***...]
Invention may be extended by mutual written agreement of UNIVERSITY and LICENSEE. UNIVERSITY agrees that, prior to and during the applicable Option Term, [...***...]. LICENSEE shall exercise its option hereunder by providing to UNIVERSITY
written notice of such exercise prior to the expiration of the applicable Option Term. Following receipt of such election notice, the parties shall commence in good faith negotiations on the terms of such license. Such license shall contain
commercially reasonable terms typically contained in license agreements pertaining to [...***...]. Any failure by LICENSEE to exercise its rights with respect to any particular [...***...] Invention shall not affect its rights under this
Section 2.6 or constitute a waiver of such rights with respect to any other [...***...] Invention. 

ARTICLE 3 

PAYMENTS 
 3.1 In partial consideration of the rights granted by this License Agreement, LICENSEE shall pay to PSRF a non-refundable, License Issue Fee of [...***...] upon execution of this License
Agreement. Said License Issue Fee shall be paid upon the Effective Date of this License Agreement. 
 3.2 LICENSEE shall
issue to UNIVERSITY forty thousand (40,000) shares of Genomatica, Inc. common stock upon the filing of the U.S. Patent Application claiming priority to U.S. Provisional Patent Application No. [...***...]. UNIVERSITY shall file such patent
application on or before [...***...]. 
 3.3 LICENSEE shall issue to UNIVERSITY ten thousand (10,000) shares
of Genomatica, Inc. common stock within [...***...] after the issue date of the first U.S. Patent included in the PATENT RIGHTS. 

  

					
		 	3.	  	***Confidential Treatment Requested

 3.4 All monetary payments due hereunder are expressed in and shall be paid by check
payable in United States of America currency, without deduction of exchange, collection or other charges, to PSRF in University Park, PA or at such other place as PSRF may reasonably designate. 

3.5 For converting into United States dollars any payment accrued hereunder in the currency of any other country, the rate of
exchange for the purchase of United States dollars with such currency quoted by The Chase Manhattan Bank, New York, New York, on the last business day of the payment period in question shall be used. 

3.6 All stock issued will be Common Stock subject to the terms and conditions, and the representations and warranties contained in
the Investment Representation Letter attached hereto as Appendix A. PSRF’s ownership of Common Stock shall be as represented in the capitalization table attached as Appendix B. 

3.7 All payments set forth in this Agreement shall, if overdue, bear interest until payment at a per annum rate of
[...***...] on the due date. The payment of such interest shall not foreclose PSRF from exercising any other rights it may have as a consequence of the lateness of any payment. 

3.8 LICENSEE’s failure to make payments in accordance with Paragraphs 3.1, 3.2, or 3.3 shall constitute a material breach or
default and shall be grounds for termination of this License Agreement pursuant to Paragraph 13.3 hereof. 
 ARTICLE 4

 MARKETING EFFORTS 
 4.1 LICENSEE shall use reasonable efforts to diligently bring one or more LICENSED PRODUCTS into the commercial market as soon as practicable and to continue active, diligent marketing efforts for
one or more LICENSED PRODUCTS throughout the term of this License Agreement. 
 4.2 LICENSEE’s failure to perform in
accordance with Paragraph 4.1 for a period of [...***...] upon written notice thereof to LICENSEE. 
 4.3 In
the event that LICENSEE in its sole discretion decides to market one or more LICENSED PRODUCTs in any country, then LICENSEE shall exert reasonable efforts to have such LICENSED PRODUCTs cleared for marketing by the responsible government agencies
of that country requiring such clearance. Should LICENSEE terminate this License Agreement, LICENSEE agrees to assign its full right, title, and interest in and to such market clearance application, including all data relating thereto, to PSRF
[...***...]. 

  

					
		 	4.	  	***Confidential Treatment Requested

 ARTICLE 5 
 PATENT PROSECUTION AND MAINTENANCE 
 5.1 Prosecution and
Maintenance. PSRF shall apply for, seek prompt issuance of, and maintain the PATENT RIGHTS during the term of this Agreement. The prosecution, filing and maintenance of patent applications and patents which issue therefrom shall be the primary
responsibility of PSRF, or its designee, but wherever practical, LICENSEE shall be given the opportunity to review and comment upon the breadth and coverage of said patent applications. During the patent preparation, prosecution and maintenance
process, LICENSEE shall have reasonable opportunities to advise PSRF to ensure that said PATENT RIGHTS adequately address the commercial and business needs of LICENSEE. 
 5.2 Cooperation of the Parties. Each party agrees to cooperate fully in the preparation, filing, and prosecution of any PATENT RIGHTS under this Agreement. Such cooperation includes, but is
not limited to: 
 (a) executing all papers and instruments, or requiring its employees or agents, to execute such papers
and instruments, so as to effectuate the ownership of INVENTIONS and PATENT RIGHTS, and to enable the other party to apply for and to prosecute patent applications in any country; and 

(b) promptly informing the other party of any matters coming to such party’s attention that may affect the preparation,
filing, or prosecution of any such patent applications. 
 5.3 U.S. Patent Filings. LICENSEE shall reimburse PSRF
for all reasonable and ordinary fees and external costs actually incurred in connection with the filing, prosecution, maintenance and defense of U.S. provisional and non-provisional patent applications and resulting patents, pursuant to the
conditions set forth herein. PSRF shall promptly provide copies of invoices for all such expenses and LICENSEE shall make payment thereof within thirty (30) days of receipt thereof. 

5.4 International Patent Filings. LICENSEE understands and agrees that the primary responsibility for the costs of all
foreign patent filings shall be LICENSEE’s, and that LICENSEE’s failure to timely communicate its decision regarding foreign filing and payment thereof may result in a loss of rights to LICENSEE. PSRF shall provide LICENSEE with all
information necessary for LICENSEE to establish relevant filing deadlines related to foreign patent applications. PSRF shall apply for, seek prompt issuance of, and maintain PATENT RIGHTS in those foreign jurisdictions designated by LICENSEE.
LICENSEE shall notify PSRF no later than three (3) months before applicable bar dates, as to the foreign countries in which it wishes PSRF to seek, or continue to seek, patent protection. Payment of all fees and costs relating to the
preparation, filing, prosecution and maintenance of said foreign PATENT RIGHTS shall be the direct responsibility of LICENSEE, provided LICENSEE is kept reasonably informed and given advance estimates where practical. If LICENSEE does not provide
payment of such fees and costs reasonably in advance of any applicable bar date, 

  
 5. 

 
LICENSEE agrees that said non-payment shall constitute a binding waiver of any right to obtain said foreign protection and LICENSEE holds PSRF harmless from any claim based thereon. 

5.5 Abandonment. In the event LICENSEE decides not to continue paying the fees and costs associated with the filing,
prosecution or maintenance of any PATENT RIGHTS, LICENSEE shall timely notify PSRF in writing in order that PSRF may continue said filing, prosecution or maintenance of such intellectual property at its own expense. LICENSEE’s right under this
License Agreement to any claims contained within the PATENT RIGHTS for any country in which LICENSEE does not continue paying the fees and costs associated with prosecution or maintenance in accordance with paragraph 5.1, 5.3 or 5.4 above shall
immediately terminate upon receipt of such notice, but only for the applicable country or countries. 
 5.6 Grounds
for Material Breach. Subject to Section 5.5, LICENSEE’s failure to make payments in accordance with Paragraph 5.3 and 5.4 shall constitute a material breach or default and shall be grounds for termination of this License Agreement
pursuant to Article XII hereof. 
 ARTICLE 6 
 INFRINGEMENT AND OTHER ACTIONS 
 6.1 LICENSEE and PSRF shall
promptly provide written notice, to the other party, of any alleged infringement by a third party of any patent licensed hereunder under PATENT RIGHTS and provide such other party with any available evidence of such infringement. 

6.2 Both parties shall use their best efforts in cooperating with each other to terminate such infringement without litigation.
For so long as [...***...] shall have the first right, but not the obligation, at its cost and expense, to bring and control any action or proceeding with respect to such infringement of PATENT RIGHTS by a third party (or any declaratory
judgment action alleging invalidity or noninfringement of any of the PATENT RIGHTS) with counsel of its own choice, and [...***...] may, for such purposes, join [...***...] as a party plaintiff. [...***...] shall have the right, at
its own expense, to be represented in any such action with counsel of its own choice. If [...***...] fails to bring an action or proceeding [...***...] shall have the right, but not the obligation, to bring and control any such action at
its own expense and by counsel of its own choice, and [...***...] shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. In the event a party brings an infringement action, the other party
shall cooperate fully, including if required to bring such action, the furnishing of a power of attorney. Neither party shall have the right to settle any patent infringement litigation under this Section 6.2 in a manner that diminishes the
rights or interests of the other party without the prior written consent of such other party. Except as otherwise agreed to by the parties as part of a cost-sharing arrangement, any recovery realized as a result of such litigation, after
reimbursement of any litigation expenses shall be retained by the party bringing such action. 

  

					
		 	6.	  	***Confidential Treatment Requested

 6.3 [...***...] shall have the first right to control any defense of any claim
involving alleged infringement of third party rights by the PATENT RIGHTS or [...***...], at its own expense and by counsel of its own choice, and [...***...] shall have the right, at its own expense, to be represented in any such action
by counsel of its own choice. [...***...] shall have the right to control any such defense of such claim at its own expense and by counsel of its own choice, and [...***...] shall have the right, at its own expense, to be represented in
any such action by counsel of its own choice. Neither party shall have the right to settle any patent infringement litigation under this Section 6.3 in a manner that diminishes the rights or interests of the other party without the consent of
such other party. 
 6.4 LICENSEE, during the exclusive period of this License Agreement, shall have the
[...***...] rights in accordance with the terms and conditions herein to sublicense any alleged infringer in the TERRITORY for the FIELD for future use of the PATENT RIGHTS. 

ARTICLE 7 

INDEMNIFICATION 
 7.1 LICENSEE shall at all times during the term of this License Agreement and thereafter, indemnify, defend and hold PSRF, its trustees, directors, officers, employees and affiliates, harmless
against all claims, proceedings, demands and liabilities of any kind whatsoever, including legal expenses and reasonable attorneys’ fees, arising out of the death of or injury to any person or persons or out of any damage to property, or
resulting from the production, manufacture, sale, use, lease, consumption or advertisement of the LICENSED PRODUCTs by LICENSEE or any of its sublicensees or arising from any obligation of LICENSEE hereunder. 

7.2 [...***...], LICENSEE shall obtain and carry in full force and effect commercial, general liability insurance which
shall protect LICENSEE and PSRF with respect to events covered by Paragraph 7.1 above. Such insurance shall be written by a reputable insurance company authorized to do business in the Commonwealth of Pennsylvania, shall list PSRF as an
additional named insured thereunder, shall be endorsed to include product liability coverage and shall require [...***...] written notice to be given to PSRF prior to any cancellation or material change thereof. The limits of such insurance
shall not be less than [...***...] per occurrence with an aggregate of [...***...] for personal injury or death, and [...***...] per occurrence with an aggregate of [...***...] for property damage. LICENSEE shall provide PSRF
with Certificates of Insurance evidencing the same. 
 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS LICENSE AGREEMENT, PSRF, ITS TRUSTEES,
DIRECTORS, OFFICERS, EMPLOYEES, AND AFFILIATES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO 

  

					
		 	7.	  	***Confidential Treatment Requested

 
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE.
NOTHING IN THIS LICENSE AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY PSRF THAT THE PRACTICE BY LICENSEE OF THE LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY. IN NO EVENT SHALL PSRF,
ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES OR LICENSEE, ITS DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST
PROFITS, REGARDLESS OF WHETHER ANY SUCH PARTY SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY. 
 ARTICLE 8 
 EXPORT CONTROLS 

8.1 It is understood that PSRF is subject to United States laws and regulations controlling the export of technical data, computer
software, laboratory prototypes and other commodities (including the Arms Export Control Act, as amended and the Export Administration Act of 1979), and that its obligations hereunder are contingent on compliance with applicable United States export
laws and regulations. The transfer of certain technical data and commodities may require a license from the cognizant agency of the United States Government and/or written assurances by LICENSEE that LICENSEE shall not export data or commodities to
certain foreign countries without prior approval of such agency. PSRF neither represents that a license shall not be required nor that, if required, it shall be issued. 
 ARTICLE 9 
 NON-USE OF NAMES 

9.1 LICENSEE shall not use the names or trademarks of Penn State, PSRF, or any of their employees, or any adaptation thereof, in
any advertising, promotional or sales literature without prior written consent obtained from PSRF, in each case, except that LICENSEE may, without prior written consent, state that it is licensed by PSRF, under one or more of the patents and/or
applications comprising the PATENT RIGHTS. 
 ARTICLE 10 

PAYMENTS, NOTICES AND OTHER COMMUNICATIONS 
 10.1 Any payment, notice or other communication pursuant to this License Agreement shall be sufficiently made or given on the date of mailing if sent to such party by certified or registered first
class mail, postage prepaid, addressed to it at its address below or as it shall designate by written notice given to the other party as follows: 

  

					
		 	8.	  	***Confidential Treatment Requested

 In the case of THE PENN STATE RESEARCH FOUNDATION: 

President 
 The Penn State Research Foundation 
 c/o Intellectual Property
Office 
 113 Technology Center 

University Park, PA 16802-7000 
 In the case of LICENSEE: 
 Thomas A. Reed 

Vice President Finance and Corporate Development 

Genomatica, Inc. 
 5405 Morehouse Drive 
 Suite 210 

San Diego, CA 92121 
 ARTICLE 11 
 ASSIGNMENT 

11.1 This License Agreement shall not be assignable by either party without the prior written consent of the other party except to
a successor in ownership of all or substantially all of the business assets of a party hereto related to this Agreement, and which successor shall expressly assume in writing the performance of all the terms and conditions of this License Agreement
to be performed by the assigning party. 
 ARTICLE 12 

DISPUTE RESOLUTION 
 12.1 Except for the right of either party to apply to a court of competent jurisdiction for a temporary restraining order, a preliminary injunction, or other equitable relief to preserve the
status quo or prevent irreparable harm, any and all claims, disputes or controversies arising under, out of, or in connection with this License Agreement, including any dispute relating to patent validity or infringement, which the parties
shall be unable to resolve within [...***...], shall be mediated in good faith. The party raising such dispute shall promptly advise the other party of such claim, dispute or controversy in a writing which describes in reasonable detail the
nature of such dispute. By not later than [...***...] after the recipient has received such notice of dispute, each party shall have selected for itself a representative who shall have the authority to bind such party, and shall additionally
have advised the other party in writing of the name and title of such representative. By not later than [...***...] after the date of such notice of dispute, the party against whom the dispute shall be raised shall select a mediation firm
[...***...] and such representatives shall schedule a date with such firm for a mediation hearing. The parties shall enter into good faith mediation [...***...]. If the representatives of the parties have not been able to resolve the
dispute within [...***...] after such mediation hearing, the parties shall have the 

  

					
		 	9.	  	***Confidential Treatment Requested

 
right to pursue any other remedies legally available to resolve such dispute in [...***...], to whose jurisdiction for such purposes PSRF and LICENSEE each hereby irrevocably consents and
submits. 
 12.2 Notwithstanding the foregoing, nothing in this Article XII shall be construed to waive any rights or
timely performance of any obligations existing under this License Agreement. 
 ARTICLE 13 

TERM AND TERMINATION 
 13.1 LICENSEE shall have the right to terminate this Agreement at any time on six (6) months’ notice to PSRF, and upon payment of all amounts due PSRF through the effective date of the
termination. 
 13.2 Financial Solvency of LICENSEE. LICENSEE agrees that as a part of its material inducement to
PSRF to enter this License Agreement, it shall provide PSRF with at least ninety (90) days written notice hereunder of its intent to file a petition in Bankruptcy, whether it be for a Chapter 7, 11, 13 or any other such petition. LICENSEE
agrees and understands that PSRF has an obligation to University, a land grant institution under the Morrell Act, to license the PATENT RIGHTS pursuant to terms and conditions which maximize the public benefit. PSRF shall have the right to
immediately terminate this License Agreement by giving written notice to LICENSEE, in the event LICENSEE does any of the following: a) provides notice hereunder of its intent to file (or does actually file without providing said notice) a petition
in bankruptcy, b) attempts to make an assignment hereof for the benefit of creditors, c) discontinues or dissolves its business, or d) if a receiver is appointed for LICENSEE. 
 13.3 Financial Breach. In the event LICENSEE has breached its obligations to pay fees or equity under Article III of this License Agreement, (hereafter “Financial Breach”) PSRF
shall provide LICENSEE with written notice of said breach, and LICENSEE shall have a period of thirty (30) days to cure said breach. In the event LICENSEE does not fully cure the breach within that thirty (30) day period, and fails within
that thirty (30) days to commence mediation pursuant to Article XII of this License Agreement alleging grounds for its non-payment thereof, this License Agreement shall be automatically terminated without further notice or action by PSRF.
Notwithstanding LICENSEE’s rights to cure herein, in the event LICENSEE commits a Financial Breach more than [...***...] within any calendar year within the term of this License, PSRF shall be entitled to give notice of breach which shall
become effective immediately upon LICENSEE’s receipt of said Notice, and for which LICENSEE shall not have any further right of “cure.” 
 13.4 Failure of Other Performance. Upon any material breach of performance under this License Agreement, by LICENSEE, other than those occurrences set out in Paragraphs 13.2 or 13.3
hereinabove, which shall always take precedence in that order over any material breach or default referred to in this Paragraph 13.4, PSRF shall have the right to terminate this License Agreement and the rights, privileges and license granted
hereunder effective sixty (60) days after 

  

					
		 	10.	  	***Confidential Treatment Requested

 
PSRF first notifies LICENSEE of the alleged breach under the notice provisions contained in Article X of this License Agreement. As used in this License Agreement, the term “Material
Breach of Performance” shall include, but not be limited to the following: [...***...]. Such termination shall become effective upon final notification by PSRF after the sixty (60) days, unless LICENSEE shall have fully cured any
such material breach or default prior to the expiration of the sixty (60) day period. In the event of a dispute as to whether LICENSEE has cured the alleged breach, the matter shall be resolved pursuant to Article XII of this License Agreement.

 13.5 Upon termination of this License Agreement for any reason, nothing herein shall be construed to release either
party from any obligation that matured prior to the effective date of such termination; and Articles I, VII, VIII, IX, XIV and paragraphs 13.5 and 13.6 shall survive any such termination. LICENSEE and any sublicensee thereof may, however, after the
effective date of such termination, sell all LICENSED PRODUCTs, and complete LICENSED PRODUCTs in the process of manufacture at the time of such termination and sell the same. 
 13.6 Upon termination of this Agreement for any reason, any sublicensee not then in default shall have the right to seek a license from PSRF. PSRF agrees to negotiate such licenses in good faith
under reasonable terms and conditions; provided, however, that LICENSEE may submit a proposed sublicense to PSRF in advance for PSRF’s prior approval, such approval not to be unreasonably withheld or delayed (i.e. PSRF will respond within
forty-five (45) days after receipt of such proposal from LICENSEE), and if PSRF approves such sublicense, then such sublicense shall also become a direct license between the sublicensee and PSRF upon termination of this Agreement for any
reason, provided that such sublicensee is not the cause of the termination of this Agreement. 
 ARTICLE 14 

 MISCELLANEOUS PROVISIONS 
 14.1 Entire Agreement. This License Agreement embodies the entire understanding of the parties and shall supersede all previous communications, representations, or undertakings, either
verbal or written, between the parties relating to the subject matter hereof. 
 14.2 Amendment. This License
Agreement may be amended only by a written agreement embodying the full terms of the amendment signed by authorized representatives of both parties. 
 14.3 Severability. Should any provision of this License Agreement be held to be illegal, invalid or unenforceable, by any court of competent jurisdiction, such provision shall be modified by
such court in compliance with the law and, as modified, enforced. The remaining provisions of this License Agreement shall be construed in accordance with the modified provision and as if such illegal, invalid or unenforceable provision had not been
contained herein. 

  

					
		 	11.	  	***Confidential Treatment Requested

 14.4 No Strict Construction. The language used in this License Agreement shall
be deemed to be the language chosen by both parties hereto to express their mutual intent and no rule of strict construction against either party shall apply to any term or condition of this License Agreement. 

14.5 Relationship of Parties. Nothing contained in this License Agreement shall be construed as creating a partnership,
joint venture, agency or an association of any kind. 
 14.6 No Waiver. The failure of one party hereto to enforce
at any time any of the provisions of this License Agreement, or any rights in respect thereto, or to exercise any election herein provided, shall in no way be considered to be a waiver of such provision, rights or elections or in any way to affect
the validity of this License Agreement, or excuse a similar subsequent failure to perform any such term or condition by the other party. Any waiver must be in writing. 
 14.7 Interpretation. The headings of several sections contained herein are inserted for convenience of reference only, and are not intended to be a part of or to affect the meaning or
interpretation of this License Agreement. 
 14.8 Governing Law. This License Agreement shall be governed by and
construed in accordance with the laws of [...***...] without giving effect to any choice of law or conflict of law provision or rule that would cause the application of the laws of any jurisdiction other than [...***...], except that
questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent was granted. 
 14.9 Product Marking. LICENSEE agrees to mark the LICENSED PRODUCTs sold in the United States with all applicable United States patent numbers. All LICENSED PRODUCTs shipped to or sold in
other countries shall be marked in such a manner as to conform with the patent laws and practices of the country of manufacture or sale. 
 14.10 Counterparts. This Agreement may be signed in one or more counterparts, by facsimile, or both, each of which will be considered an original, all of which will constitute the same
instrument. 

  

					
		 	12.	  	***Confidential Treatment Requested

 IN WITNESS WHEREOF, the parties hereto, intending to be legally bound hereby, have each
caused a duly authorized representative to execute this License Agreement on the day and year set forth below. 
 GENOMATICA, INC.

 (LICENSEE) 
  

			
	 By:
	 	 /s/ Bernhard Palsson

	 Name:
	 	Bernhard Palsson
	 Title:
	 	Chief Executive Officer
	 Date:
	 	December 20, 2001
	
	THE PENN STATE RESEARCH FOUNDATION
		
	 (PSRF)
	 	
		
	 By:
	 	 /s/ David E. Branigan

	 Name:
	 	David E. Branigan
	 Title:
	 	Treasurer
	 Date:
	 	February 12, 2002

  
 13.

 APPENDIX A 
 January 9, 2002 
 Genomatica, Inc. 
 5405 Morehouse Drive 
 Suite 210 
 San Diego, CA 92121 
 Ladies and Gentlemen: 

The undersigned hereby makes the following certifications and representations with respect to the forty thousand (40,000) shares (the
“Shares”) of Common Stock of GENOMATICA, INC., a California corporation (the “Company”), which are being acquired by the undersigned pursuant to the License Agreement by and between the Company and
the undersigned. 
 The undersigned represents and warrants that it is acquiring said shares solely for its account for investment and not with
a view to or for sale or distribution of said shares or any part thereof. The undersigned also represents that the entire legal and beneficial interests of the shares the undersigned is acquiring is being acquired for, and will be held for, its
account only. 
 The undersigned understands that[ the shares have not been registered under the Securities Act of 1933, as amended (the
“Act”), on the basis that no distribution or public offering of the shares is to be effected. The undersigned realizes that the basis for the exemption may not be present if, notwithstanding its representations, it has in mind merely
acquiring the securities for a fixed or determinable period in the future, or for a market rise, or for sale if the market does not rise. The undersigned has no such intention. 
 The undersigned recognizes that the shares being acquired by it must be held indefinitely unless they are subsequently registered under the Act or an exemption from such registration is available. The
undersigned recognizes that the Company has no obligation to register the shares or to comply with any exemption from such registration. 
 The
undersigned is aware that the shares may not be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met and until the undersigned has held the shares for at least one year. Among the conditions for use of the Rule is the
availability of current information to the public about the Company. The undersigned understands that the Company has not made such information available and has no present plans to do so. 
 The undersigned further agrees not to make any disposition of all or any part of the shares being acquired in any event unless and until: 

1. The Company shall have received a letter secured by the undersigned from the Securities and Exchange Commission stating
that no action will be recommended to the Commission with respect to the proposed disposition; or 

  
 1. 

 2. There is then in effect a registration statement under the Act covering
such proposed disposition and such disposition is made in accordance with said registration statement; or 

3.(i) The undersigned shall have notified the Company of the proposed disposition and shall have furnished the Company
with a detailed statement of the circumstances surrounding the proposed disposition, (ii) the undersigned shall have furnished the Company with an opinion of counsel for the undersigned to the effect that such disposition will not require
registration of such shares under the Act, and (iii) such opinion of counsel for the undersigned shall have been concurred in by the Company’s counsel and the Company shall have advised the undersigned of such concurrence. 

If requested by the Company and an underwriter of Common Stock (or other securities) of the Company, the undersigned shall not sell or otherwise transfer
or dispose of any Shares (or other securities) of the Company then owned by the undersigned (other than those included in such registration) during the one hundred eighty (180) day period (or such lessor period as is permitted by the
underwriter) following the effective date of a registration statement of the Company filed under the Securities Act. 
 The undersigned
understands and agrees that all certificates evidencing the shares to be issued to the undersigned may bear the following legends: 
 “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.” 
 “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RIGHT OF FIRST REFUSAL OPTION IN FAVOR OF THE COMPANY AND/OR ITS ASSIGNEE(S), AS PROVIDED IN THE BYLAWS OF THE COMPANY.” 

Very truly yours, 
 THE
PENN STATE RESEARCH FOUNDATION 
  

			
	 By:
	 	 /s/ David E. Branigan

	 Name:
	 	 David E. Branigan

	 Title:
	 	 Treasurer

  
 2. 

 ADDENDUM TO THE LICENSE AGREEMENT 

This Addendum (hereinafter referred to as the “Addendum”), effective on June 26 , 2003 (hereinafter the
“Effective Date”), is by and between the PENN STATE RESEARCH FOUNDATION, a non-profit corporation duly organized and existing under the laws of the Commonwealth of Pennsylvania and having an office at 304 Old Main, University Park,
Pennsylvania 16802 (hereinafter referred to as “PSRF”), and Genomatica, Inc., a corporation organized under the laws of California (hereinafter referred to as “LICENSEE”), having its principal office at 5405 Morehouse Drive,
Suite 210, San Diego, CA 92121. All capitalized terms not otherwise defined herein shall have the meanings given to them in the License Agreement (as defined below). 
 WHEREAS, PSRF and LICENSEE entered into a License Agreement (the “License Agreement”), effective February 12, 2002, whereby PSRF granted LICENSEE an exclusive right and license in the
Territory for the Field, with the right to sublicense, to Patent Rights and to make, have made, use, lease, sell, have sold, offer for sale, and import Licensed Products; 
 WHEREAS, pursuant to Paragraph 2.6 of the License Agreement, LICENSEE has the option to acquire an exclusive, worldwide license to certain inventions related to the rights obtained under the License
Agreement; 
 WHEREAS, [...***...], employees of The Pennsylvania State University (hereinafter referred to as
“UNIVERSITY”), have invented [...***...]; 
 WHEREAS, PSRF has informed LICENSEE [...***...], as required
under Paragraph 2.6 of the License Agreement; 
 WHEREAS, PSRF is the owner of patent rights relating to [...***...] and
has the right to grant licenses under such patent rights; 
 WHEREAS, LICENSEE has represented that it wishes to obtain
exclusive rights to [...***...]; and 
 WHEREAS, PSRF desires to have [...***...] utilized in the public interest
and is willing to grant a license to PSRF’s rights hereunder. 
 Now, therefore, and in consideration for the foregoing and
the covenants and promises hereinafter set forth, the parties hereto agree as follows: 
 1. Paragraph 1.5 of the License Agreement is replaced
in its entirety as follows: 
 1.5 “PATENT RIGHTS” shall mean all of the following without limitation; 

(a) U.S. Provisional Patent Application No. [...***...], filed on [...***...], together with all pending and issued
U.S. and foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations,

  

					
		 	1.	  	***Confidential Treatment Requested

 
continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or
foreign counterparts filed and prosecuted pursuant to Article 6 and; 
 (b) U.S. Provisional Patent Application No.
[...***...], filed [...***...], together with all pending and issued U.S. and foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and
issued renewals, re-examinations, continuations, continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or
foreign counterparts filed and prosecuted pursuant to Article 6 and; 
 (c) U.S. Provisional Patent Application No.
[...***...], filed on [...***...], together with all pending and issued U.S. and foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and
issued renewals, re-examinations, continuations, continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or
foreign counterparts filed and prosecuted pursuant to Article 6 and; 
 (d) U.S. Provisional Patent Application No.
[...***...], filed on [...***...], together with all pending and issued U.S. and foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and
issued renewals, re-examinations, continuations, continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or
foreign counterparts filed and prosecuted pursuant to Article 6 and; 
 (e) U.S. Provisional Patent Application No.
[...***...], filed on [...***...], together with all pending and issued U.S. and foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and
issued renewals, re-examinations, continuations, continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or
foreign counterparts filed and prosecuted pursuant to Article 6. 
 2. Paragraph 3.6 of the License Agreement is replaced in its entirety as
follows: 
 3.6 All stock issued will be Common Stock subject to the terms and conditions, and the representations and warranties
contained in the Investment Representation Letters attached hereto as Appendix A and Appendix A-1, as applicable. PSRF’s ownership of Common Stock shall be as represented in the capitalization table attached as Appendix B. 

3. Paragraph 3.9 is added to the License Agreement as follows: 

  

					
		 	2.	  	***Confidential Treatment Requested

 3.9 LICENSEE shall issue to UNIVERSITY twenty five thousand (25,000) shares of
Genomatica, Inc. common stock upon the filing of the U.S. Patent Application or counterpart PCT application claiming priority to U.S. Provisional Patent Application [...***...]. UNIVERSITY shall file such patent application on or before
[...***...]. 
 4. Appendix A-1 hereto is added to the License Agreement. 
 5. Appendix B to the License Agreement is replaced with Appendix B hereto. 
 6. PSRF has
sufficient rights and power to grant the license to LICENSEE which it purports to grant by this Addendum. 
 7. Except as specifically set forth
by this Addendum, the terms and conditions of the License Agreement shall remain in full force and effect. This Addendum may be executed in two counterparts, each of which shall be deemed an original, but both of which together shall constitute one
and the same instrument. 

  

					
		 	3.	  	***Confidential Treatment Requested

 IN WITNESS WHEREOF, the parties hereto have executed this Addendum, in duplicate, by proper
persons thereunto duly authorized. 
  

			
	 PENN STATE RESEARCH FOUNDATION

		
	 By:
	 	 /s/ David E. Branigan

	 Name:
	 	 David E. Branigan

	 Title:
	 	 Treasurer

	 Date:
	 	 July 11, 2003

	
	 GENOMATICA, INC.

		
	 By:
	 	 /s/ Christophe Schilling

	 Name:
	 	 Christophe Schilling

	 Title:
	 	 V.P. & Chief Technical Officer

	 Date:
	 	 July 8, 2003

 Appendix A-1 
 June 26, 2003 
 Genomatica, Inc. 
 5405 Morehouse Drive 
 Suite 210 
 San Diego, CA 92121 
 Ladies and Gentlemen: 

The undersigned hereby makes the following certifications and representations with respect to the twenty-five thousand (25,000) shares (the
“Shares”) of Common Stock of GENOMATICA, INC., a California corporation (the “Company”), which are being acquired by the undersigned pursuant to the License Agreement (including the Addendum thereto)
by and between the Company and the undersigned. 
 The undersigned represents and warrants that it is acquiring said shares solely for its
account for investment and not with a view to or for sale or distribution of said shares or any part thereof. The undersigned also represents that the entire legal and beneficial interests of the shares the undersigned is acquiring is being acquired
for, and will be held for, its account only. 
 The undersigned understands that the shares have not been registered under the Securities Act of
1933, as amended (the “Act”), on the basis that no distribution or public offering of the shares is to be effected. The undersigned realizes that the basis for the exemption may not be present if, notwithstanding its representations, it
has in mind merely acquiring the securities for a fixed or determinable period in the future, or for a market rise, or for sale if the market does not rise. The undersigned has no such intention. 

The undersigned recognizes that the shares being acquired by it must be held indefinitely unless they are subsequently registered under the Act or an
exemption from such registration is available. The undersigned recognizes that the Company has no obligation to register the shares or to comply with any exemption from such registration. 
 The undersigned is aware that the shares may not be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met and until the undersigned has held the shares for at least one year.
Among the conditions for use of the Rule is the availability of current information to the public about the Company. The undersigned understands that the Company has not made such information available and has no present plans to do so. 

The undersigned further agrees not to make any disposition of all or any part of the shares being acquired in any event unless and until: 

 

	1.	The Company shall have received a letter secured by the undersigned from the Securities and Exchange Commission stating that no action will be recommended to the
Commission with respect to the proposed disposition; or 

  
 1. 

	2.	There is then in effect a registration statement under the Act covering such proposed disposition and such disposition is made in accordance with said registration
statement; or 

  

	3.(i)	The undersigned shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances
surrounding the proposed disposition, (ii) the undersigned shall have furnished the Company with an opinion of counsel for the undersigned to the effect that such disposition will not require registration of such shares under the Act, and
(iii) such opinion of counsel for the undersigned shall have been concurred in by the Company’s counsel and the Company shall have advised the undersigned of such concurrence. 

If requested by the Company and an underwriter of Common Stock (or other securities) of the Company, the undersigned shall not sell or otherwise transfer
or dispose of any Shares (or other securities) of the Company then owned by the undersigned (other than those included in such registration) during the one hundred eighty (180) day period (or such lessor period as is permitted by the
underwriter) following the effective date of a registration statement of the Company filed under the Act. 
 The undersigned
understands and agrees that all certificates evidencing the shares to be issued to the undersigned may bear the following legends: 
 “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.” 
 “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RIGHT OF FIRST REFUSAL OPTION IN FAVOR OF THE COMPANY AND/OR ITS ASSIGNEE(S), AS PROVIDED IN THE BYLAWS OF THE COMPANY.” 

Very truly yours, 
  

			
	THE PENN STATE RESEARCH FOUNDATION
		
	By:	 	 /s/ David E. Branigan

			
		
	Name:	 	 David E. Branigan

			
		
	Title:	 	 Treasurer

			
		
	Date:	 	July 11, 2003

  
 2. 

 Appendix B 
 [...***...] 
  

									
	 	 	 	 	 [...***...]
	 	 [...***...]
	 	 
					
		 	 [...***...]
	 	[...***...]	 	[...***...]	 	
					
		 	 [...***...]
	 	[...***...]	 	[...***...]	 	
					
		 	 [...***...]
	 	[...***...]	 	[...***...]	 	
					
		 	 [...***...]
	 	[...***...]	 	[...***...]	 	
					
		 	 [...***...]
	 	[...***...]	 	[...***...]	 	

  

					
		 		  	***Confidential Treatment Requested

			
	 The Penn State

Research Foundation
	  	 The Pennsylvania State University
 304 Old Main
 University Park, PA 16802-1504

814-865-6331
 814-863-9659
(fax)

 April 15, 2005 
 Christophe H. Schilling, Ph.D. 
 President & CSO 

GENOMATICA, INC. 
 5405 Morehouse Drive, Suite
210 
 San Diego, CA 92121 
  

	RE:	February 12, 2002 License Agreement between Genomatica, Inc. and The Penn State Research Foundation (“PSRF”) 

Dear Dr. Schilling: 
 We
have reviewed your April 5, 2005 email correspondence and are in agreement with your suggested revision to the following amendment to Section 2.6. 
 2.6 UNIVERSITY hereby grants to LICENSEE an exclusive option to acquire an exclusive, worldwide license (with the right to sublicense) to develop, make, have made, use, sell, have sold, offer for sale and
import products and employ methods covered by or incorporating any [...***...] invention, [...***...] during the term of this Agreement (each, a “[...***...] Invention”). UNIVERSITY shall promptly notify LICENSEE in
writing of any such [...***...] Invention. With respect to any specific [...***...] Invention, such option shall extend for a period of [...***...] following the date of [...***...] in writing to LICENSEE by UNIVERSITY of
[...***...] (the “Option Term”). The Option Term with respect to any particular [...***...] Invention may be extended by mutual written agreement of UNIVERSITY and LICENSEE. UNIVERSITY agrees that, prior to and during the
applicable Option Term, it shall [...***...]. LICENSEE shall exercise its option hereunder by providing to UNIVERSITY written notice of such exercise prior to the expiration of the applicable Option Term. Following receipt of such election
notice, the parties shall commence in good faith negotiations on the terms of such license. Such license shall contain commercially reasonable terms typically contained in license agreements pertaining to [...***...]. Any failure by LICENSEE
to exercise its rights with respect to any particular [...***...] Invention shall not affect its rights under this Section 2.6 or constitute a waiver of such rights with respect to any other [...***...] Invention. 

Except as specifically set forth by this Letter Agreement, the terms and conditions of the February 12, 2002 License Agreement
between Genomatica, Inc. and PSRF and the corresponding June 26, 2003 Addendum to the License Agreement shall apply. 

  

					
		 	1.	  	***Confidential Treatment Requested

 If such conditions are acceptable, please execute the two (2) originals of this letter
agreement and return the two (2) originals of this letter agreement to me, so that I may process them for signature on behalf of The Penn State Research Foundation. I will then return one (1) fully executed original to you. 

Sincerely, 
 /s/ [...***...] 
 [...***...] 

[...***...] 
  

			
	PENN STATE RESEARCH FOUNDATION
		
	By:	 	 /s/ David E. Branigan

			
		
	Name:	 	 David E. Branigan

			
		
	Title:	 	 Treasurer

			
		
	Date:	 	 April 19, 2005

	
	GENOMATICA, INC.
		
	By:	 	  

			
		
	Name:	 	  

			
		
	Title:	 	  

			
		
	Date:	 	  

  

					
		 	2.	  	***Confidential Treatment Requested

 SECOND ADDENDUM TO THE LICENSE AGREEMENT 

This Second Addendum (hereinafter referred to as the “Addendum”), effective on May 17, 2005 (hereinafter the
“Effective Date”), is by and between the PENN STATE RESEARCH FOUNDATION, a non-profit corporation duly organized and existing under the laws of the Commonwealth of Pennsylvania and having an office at 304 Old Main, University Park,
Pennsylvania 16802 (hereinafter referred to as “PSRF”), and Genomatica, Inc., a corporation organized under the laws of California (hereinafter referred to as “LICENSEE”), having its principal office at 5405 Morehouse Drive,
Suite 210, San Diego, CA 92121. All capitalized terms not otherwise defined herein shall have the meanings given to them in the License Agreement (as defined below). 
 WHEREAS, PSRF and LICENSEE entered into a License Agreement (the “License Agreement”), effective February 12, 2002 and amended pursuant to that certain Addendum between the parties dated
June 26, 2003, whereby PSRF granted LICENSEE an exclusive right and license in the Territory for the Field, with the right to sublicense, to Patent Rights and to make, have made, use, lease, sell, have sold, offer for sale, and import Licensed
Products; 
 WHEREAS, pursuant to Paragraph 2.6 of the License Agreement, LICENSEE has the option to acquire an exclusive,
worldwide license to certain inventions related to the rights obtained under the License Agreement; 
 WHEREAS,
[...***...], employees of The Pennsylvania State University (hereinafter referred to as “UNIVERSITY”), have invented (1) [...***...] (PSU Invention Disclosure No. [...***...]) (hereinafter referred to as the
[...***...]) and (2) [...***...] (PSU Invention Disclosure No. [...***...]); 
 WHEREAS, PSRF has
informed LICENSEE of the [...***...] and the [...***...], as required under Paragraph 2.6 of the License Agreement; 

WHEREAS, PSRF is the owner of patent rights relating to the [...***...]; 

WHEREAS, LICENSEE has represented that it wishes to obtain [...***...]; 

WHEREAS, PSRF desires to have the [...***...] utilized in the public interest and is willing to grant [...***...];

 WHEREAS, PSRF and LICENSEE wish to amend Paragraph 2.6 of the License Agreement [...***...]. 

Now, therefore, and in consideration for the foregoing and the covenants and promises hereinafter set forth, the parties hereto agree as
follows: 
  

	1.	Paragraph 1.5 of the License Agreement is replaced in its entirety as follows: 

  

					
		 	1.	  	***Confidential Treatment Requested

 1.5 “PATENT RIGHTS” shall mean all of the following without limitation;

 (a) U.S. Provisional Patent Application No. [...***...], filed on [...***...], together with all pending and
issued U.S. and foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations, continuations-in-part (but
only to the extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and prosecuted pursuant to Article 6 and; 

(b) U.S. Provisional Patent Application No. [...***...], filed on [...***...], together with all pending and issued U.S. and
foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations, continuations-in-part (but only to the
extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and prosecuted pursuant to Article 6 and; 

(c) U.S. Provisional Patent Application No. [...***...], filed on [...***...], together with all pending and issued U.S. and
foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations, continuations-in-part (but only to the
extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and prosecuted pursuant to Article 6 and; 

(d) U.S. Provisional Patent Application No. [...***...], filed on [...***...], together with all pending and issued U.S. and
foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations, continuations-in-part (but only to the
extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and prosecuted pursuant to Article 6; 

(e) U.S. Provisional Patent Application No[...***...], filed on [...***...], together with all pending and issued U.S. and
foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations, continuations-in-part (but only to the
extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and prosecuted pursuant to Article 6; 

(f) U.S. Patent Application No. [...***...] 

  

					
		 	2.	  	***Confidential Treatment Requested

 [...***...], filed on [...***...], together with all pending and issued U.S. and
foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations, continuations-in-part (but only to the
extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and prosecuted pursuant to Article 6; and 

(g) Any patent application of any kind or type filed with respect to [...***...], together with all pending and issued U.S. and
foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations, continuations-in-part (but only to the
extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and prosecuted pursuant to Article 6. 

 

	2.	Paragraph 2.6 of the License Agreement is replaced in its entirety as follows: 

 “2.6 UNIVERSITY hereby grants to [...***...] to develop, make, have made, use, sell, have sold, offer for sale and import products and employ methods covered by or incorporating any
[...***...] invention, [...***...] during the term of this Agreement (each, a “[...***...] Invention”). UNIVERSITY shall promptly notify LICENSEE in writing of any such [...***...] Invention. With respect to any
specific [...***...] Invention, such option shall extend for a period of [...***...] following the date of [...***...] in writing to LICENSEE by UNIVERSITY of [...***...] (the “Option Term”). The Option Term with
respect to any particular [...***...] Invention may be extended by mutual written agreement of UNIVERSITY and LICENSEE. UNIVERSITY agrees that, prior to and during the applicable Option Term, [...***...]. LICENSEE shall exercise its
option hereunder by providing to UNIVERSITY written notice of such exercise prior to the expiration of the applicable Option Term. Following receipt of such election notice, the parties shall commence in good faith negotiations on the terms of such
license. Such license shall contain commercially reasonable terms typically contained in license agreements pertaining to [...***...]. Any failure by LICENSEE to exercise its rights with respect to any particular [...***...] Invention
shall not affect its rights under this Section 2.6 or constitute a waiver of such rights with respect to any other [...***...] Invention.” 
 Notwithstanding the foregoing, for purposes of clarification, the replacement of Section 2.6 pursuant to this Addendum shall apply to [...***...] Inventions (as defined in the License
Agreement) made after the date of this Addendum. The language in Section 2.6 as it existed prior to the date of this Addendum shall apply to all [...***...] Inventions that were [...***...] prior to the date of this Addendum.

  

					
		 	3.	  	***Confidential Treatment Requested

	3.	Paragraph 3.6 of the License Agreement is replaced in its entirety as follows: 

 “3.6 All stock issued will be Common Stock subject to the terms and conditions, and the representations and warranties contained in the Investment Representation Letters attached hereto as Appendix
A. 
  

	4.	Paragraph 3.10 is added to the License Agreement as follows: 

 “3.10 LICENSEE shall issue to UNIVERSITY ten thousand (10,000) shares of Genomatica, Inc. common stock (the [...***...]”) concurrent with the execution of this Addendum.
[...***...]. [...***...] and all rights and interest therein or related thereto, and LICENSEE shall have the right to transfer to its own name the [...***...] being repurchased by the Company, without further action by
Purchaser.” 
  

	5.	PSRF has sufficient rights and power to grant the license to LICENSEE which it purports to grant by this Addendum. 

 

	6.	Except as specifically set forth by this Addendum, the terms and conditions of the License Agreement shall remain in full force and effect. This Addendum may be
executed in two counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument. 

  

					
		 	4.	  	***Confidential Treatment Requested

 IN WITNESS WHEREOF, the parties hereto have executed this Addendum, in duplicate, by proper
persons thereunto duly authorized. 
  

			
	PENN STATE RESEARCH FOUNDATION
		
	By:	 	 /s/ David E. Branigan

			
		
	Name:	 	 David E. Branigan

			
		
	Title:	 	 Treasurer

			
		
	Date:	 	 June 24, 2005

	
	GENOMATICA, INC.
		
	By:	 	 /s/ Thomas A. Reed

			
		
	Name:	 	 Thomas A. Reed

			
		
	Title:	 	 CFO

			
		
	Date:	 	 6/22/05

 Appendix A 
 June 24, 2005 
 Genomatica, Inc. 
 5405 Morehouse Drive 
 Suite 210 
 San Diego, CA 92121 
 Ladies and Gentlemen: 

The undersigned hereby makes the following certifications and representations with respect to the ten thousand (10,000) shares (the
“Shares”) of Common Stock of GENOMATICA, INC., a California corporation (the “Company”), which are being acquired by the undersigned pursuant to the License Agreement (including the Second Addendum
thereto) by and between the Company and the undersigned. 
 The undersigned represents and warrants that it is acquiring said shares solely for
its account for investment and not with a view to or for sale or distribution of said shares or any part thereof. The undersigned also represents that the entire legal and beneficial interests of the shares the undersigned is acquiring is being
acquired for, and will be held for, its account only. 
 The undersigned understands that the shares have not been registered under the
Securities Act of 1933, as amended (the “Act”), on the basis that no distribution or public offering of the shares is to be effected. The undersigned realizes that the basis for the exemption may not be present if, notwithstanding its
representations, it has in mind merely acquiring the securities for a fixed or determinable period in the future, or for a market rise, or for sale if the market does not rise. The undersigned has no such intention. 

The undersigned recognizes that the shares being acquired by it must be held indefinitely unless they are subsequently registered under the Act or an
exemption from such registration is available. The undersigned recognizes that the Company has no obligation to register the shares or to comply with any exemption from such registration. 
 The undersigned is aware that the shares may not be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met and until the undersigned has held the shares for at least one year.
Among the conditions for use of the Rule is the availability of current information to the public about the Company. The undersigned understands that the Company has not made such information available and has no present plans to do so. 

The undersigned further agrees not to make any disposition of all or any part of the shares being acquired in any event unless and until: 

  
 1. 

	1.	The Company shall have received a letter secured by the undersigned from the Securities and Exchange Commission stating that no action will be recommended to the
Commission with respect to the proposed disposition; or 

  

	2.	There is then in effect a registration statement under the Act covering such proposed disposition and such disposition is made in accordance with said registration
statement; or 

  

	3.	(i) The undersigned shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances
surrounding the proposed disposition, (ii) the undersigned shall have furnished the Company with an opinion of counsel for the undersigned to the effect that such disposition will not require registration of such shares under the Act, and
(iii) such opinion of counsel for the undersigned shall have been concurred in by the Company’s counsel and the Company shall have advised the undersigned of such concurrence. 

If requested by the Company and an underwriter of Common Stock (or other securities) of the Company, the undersigned shall not sell or otherwise transfer
or dispose of any Shares (or other securities) of the Company then owned by the undersigned (other than those included in such registration) during the one hundred eighty (180) day period (or such lessor period as is permitted by the
underwriter) following the effective date of a registration statement of the Company filed under the Act. 
 The undersigned
understands and agrees that all certificates evidencing the shares to be issued to the undersigned may bear the following legends: 
 “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.” 
 “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RIGHT OF FIRST REFUSAL OPTION IN FAVOR OF THE COMPANY AND/OR ITS ASSIGNEE(S), AS PROVIDED IN THE BYLAWS OF THE COMPANY.” 

Very truly yours, 
  

			
	THE PENN STATE RESEARCH FOUNDATION
		
	By:	 	 /s/ David E. Branigan

	Name:	 	 David E. Branigan

	Title:	 	 Treasurer

  
 2.Joint Development Agreement

 EXECUTION VERSION 
 Exhibit 10.18 
 ***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4)

 and 230.406 
 JOINT DEVELOPMENT AGREEMENT 
 Between 

Genomatica, Inc. 
 and 
 WM Organic Growth, Inc. 

THIS AGREEMENT is entered into by and between Genomatica, Inc. (“Genomatica”), a Delaware corporation, and
WM Organic Growth, Inc. (“WMOG”), a Delaware corporation, to be effective as of the 1st day of December, 2010 (the “Effective Date”). 
 In consideration of the
mutual covenants and agreements contained herein, the Parties hereto agree as follows: 
  

	1.	Definitions. 

 Capitalized
terms, when used in this Agreement, shall have the following meanings: 
 1.1. Affiliate.
“Affiliate” shall mean any person or entity directly or indirectly controlling, controlled by, or under common control with a Party, and for this purpose, “control,” “controlling” and “controlled by” shall
mean the ownership and control of more than fifty percent (50%) of the outstanding voting securities or interest in capital or profits of any person or entity, or the right to direct or control the management or affairs of any person or entity
by contract or similar arrangement. Should a Party divest an Affiliate or should an Affiliate cease to satisfy this definition, such Affiliate’s rights and obligations under this Agreement shall be terminated. 

1.2. Agreement. “Agreement” shall mean this document and all Exhibits referenced herein and attached
hereto, and all Development Plans executed by the Parties under Section 2.2, as may be amended in accordance with the terms hereof. 
 1.3. Agricultural Residues. “Agricultural Residues” shall mean by-products from the farming or harvesting of agricultural crops or forestry products. 

1.4. Background Technology. “Background Technology” shall mean all Intellectual Property first conceived,
first designed, first created, first developed, first reduced to practice or otherwise acquired by a Party prior to, or otherwise outside of the course of, the Program, including rights arising in the course of prosecution and maintenance of such
Intellectual Property, and which the Party discloses or otherwise provides to the other Party for use in the Program. 

 1.5. Confidential Information “Confidential Information”
shall mean, with respect to a Party hereto, all information, whether in written, electronic or any other form, which is disclosed to or observed by the other Party under this Agreement or was disclosed to or observed by the other Party under the NDA
and, in each case, which is or was (A) marked “Confidential”, “Restricted,” or “Proprietary Information” or other similar marking, (B) known by the Parties to be considered confidential or proprietary, or
(C) should be known or understood to be confidential or proprietary by an individual exercising reasonable commercial judgment in the circumstances. Confidential Information includes, but is not limited to, information disclosed in connection
with the Program, and proprietary information regarding the disclosing Party’s product plans, product designs, product costs, product prices, finances, marketing plans, business opportunities, Personnel, research and development activities,
Intellectual Property and pre-release products. The terms and conditions of this Agreement and the existence of this Agreement shall be Confidential Information of both Parties. The Background Technology of WMOG shall be Confidential Information of
WMOG, and the Background Technology of Genomatica and the Program Technology shall be Confidential Information of Genomatica. Confidential Information does not include information to the extent that such information: (i) is or becomes generally
known to the public by any means other than a breach of the obligations of the receiving Party hereunder; (ii) was previously known to the receiving Party as evidenced by its written records; (iii) is rightly received by the receiving
Party from a third Party who is not under an obligation of confidentiality; or (iv) is independently developed by the receiving Party without reference to or use of the disclosing Party’s Confidential Information. 

1.6. Development Plan. “Development Plan” shall mean any development plan attached hereto as Exhibit A,
and any additional development plan containing the requirements set forth in Section 2.2 and executed by the Parties, in each case as may be amended in accordance with the terms hereof. 

1.7. Field. “Field” shall mean the production of [...***...] from syngas produced primarily from
Waste materials. 
 1.8. Genomatica Process Technology. “Genomatica Process Technology” shall
mean (a) Background Technology that is (i) owned or licensed (with the right to sublicense) by Genomatica and (ii) claims or covers all or part of a Process, including the components (including microorganisms) used in a Process and
(b) Program Technology. 
 1.9. Intellectual Property. “Intellectual Property” shall mean
all inventions (whether or not protectable under patent laws), information fixed in any tangible medium of expression (whether or not protectable under copyright laws), trade secrets, Know-How, ideas (whether or not protectable under trade secret
laws), concepts, techniques and all other subject matter protectable under patent, trade secret, or other laws anywhere in the world, including without limitation all new or useful art, combinations, discoveries, formulae, chemical compositions,
manufacturing techniques, business methods, technical developments, and designs. 
 1.10. Know How.
“Know How” shall mean all factual knowledge and proprietary information, including Confidential Information and trade secrets, whether or not capable of precise separate description, but which alone or when accumulated confer upon one
acquiring it an ability to study, test, produce, manufacture and/or market something which one otherwise would not have known to study, test, produce, manufacture and/or market in the same way. 

1.11. NDA. “NDA” shall mean the Non-Disclosure Agreement between the Parties, dated August 4, 2009.

  

					
		  	2	  	***Confidential Treatment Requested

 1.12. Parties. “Parties” shall mean each of the parties to
this Agreement. “Party” means either party to this Agreement. 
 1.13. Personnel.
“Personnel” shall mean and includes a Party’s directors, officers, employees, agents, auditors, consultants and subcontractors, provided that neither Party shall be considered a subcontractor of the other Party for the purposes of
this definition, and, with respect to WMOG, the directors, officers, employees, agents, auditors, consultants and subcontractors of WMOG’s Affiliates shall be considered WMOG’s Personnel. 

1.14. Process. “Process” shall mean a microbial fermentation process to produce a chemical from syngas
[...***...]. 
 1.15. Program. “Program” shall mean the joint development program
undertaken by the Parties, as described in Section 2.1. 
 1.16. Program Technology. “Program
Technology” shall mean all Intellectual Property first conceived, first designed, first created, first developed, first reduced to practice or otherwise acquired by a Party during the course of work on the Program or under this Agreement or any
Development Plan, including rights arising in the course of prosecution and maintenance of such Intellectual Property, provided that Program Technology does not include any Background Technology. 

1.17. Stage. “Stage” shall mean each stage of the Program as described in Exhibit B. 

1.18. Territory. “Territory” shall mean North America (including the U.S., Canada and Mexico).

 1.19. Waste. “Waste” shall mean municipal solid waste; [...***...]. 

 

	2.	Intent and Purpose of Joint Development. 

 2.1. Intent and Purpose. This Agreement provides for the funding of a joint program to develop a Process to produce [...***...] from syngas sourced primarily from Waste on a commercial scale
(the “Program”). Commercialization activities with respect to such Process (including Stages 5 and 6 described in Exhibit B) are specifically excluded from the Program scope under this Agreement, and the milestones, timelines and
success payments for Stages 5 and 6 set forth in Exhibit B are not binding on the parties. 
 2.2. Development
Plan. Further details regarding the Program will be provided in the complete Development Plan for each Stage. Development Plans for each of Stages 1 through 4 are attached to this Agreement at Exhibit A. Each Development Plan shall set
forth in reasonable detail the equipment, capital, Intellectual Property, and other resources to be required, as well as the anticipated deliverables for each Stage. The Development Plans may include such additional terms and conditions as the
Parties may wish to include; provided, however, that such terms do not conflict with the terms of this Agreement. Any changes to the terms of this Agreement must be made pursuant to Section 17.10 herein. In the event of a conflict between the
terms of this Agreement and a Development Plan, the terms of this 

  

					
		  	3	  	***Confidential Treatment Requested

 
Agreement shall govern. All fully executed Development Plans shall be deemed to be attached to and incorporated into this Agreement. 

2.3. Modifications. The Development Plans may be amended by the Parties in a writing executed by both Parties.
During the term of a Development Plan, either Party may propose changes or modifications thereto. In such case, both Parties will timely review any proposed changes, and will identify impacts of such changes on the Development Plan. Any agreed upon
changes shall be described in a written amendment to the Development Plan executed by the Parties. 
  

	3.	Program Timeline and Milestones. 

 3.1. Program Timeline and Milestones. The timeline and milestones for each Stage of the Program are set forth in Exhibit B. Stage 1 will begin on the Effective Date and expire [...***...]
thereafter. Each subsequent Stage will commence only if the milestone for the prior Stage is achieved within the timeline for such prior Stage as set forth in Exhibit B, and will begin on the day following the last day of the timeline for the
previous Stage, provided, however, the timeline for any Stage shall be extended for no more than thirty (30) days upon written notice by Genomatica to WMOG that Genomatica believes it will be able to achieve such milestone within such extension
period and will use good faith efforts to do so, or may be extended upon mutual written agreement of the Parties. Genomatica shall provide written notice to WMOG of achievement of the milestone for each Stage, with appropriate supporting
documentation. 
 3.2. Failure to Achieve Milestones. [...***...] prior to the end of each Stage,
Genomatica shall provide WMOG with a status update indicating whether, in Genomatica’s good faith judgment, Genomatica believes that the milestone for such Stage will be met within the timeline for such Stage as set forth in Exhibit B.
Should Genomatica be unable to achieve the milestone for a Stage within the timeline for such Stage (as may be extended under Section 3.1 or 4.2), WMOG shall have the right to terminate this Agreement immediately by giving Genomatica written
notice, such notice to be given no later than thirty (30) days after the last day of the timeline for such Stage (as may be extended under Section 3.1 or 4.2). If WMOG does not terminate within such timeframe, the Parties will mutually
agree upon a revised timeline and/or milestone. [...***...]. For clarity, upon termination of this Agreement under this Section 3.2, the subsequent Stage shall not commence and no further Stage costs will accrue. 

 

	4.	Scope of Cooperation. 

 4.1. Performance of Development Plan. During the term of any Development Plan, the Parties will work together in a mutually beneficial and cooperative fashion in order to meet the objectives of the
Development Plan. In connection therewith, each Party agrees to use commercially reasonable efforts to perform its responsibilities and to allocate sufficient resources to complete the Program in accordance with the relevant specifications and
development schedule, if any, set forth in such Development Plan. For clarity, the failure of a Party to achieve any scientific or technical result contemplated under the Development Plan, including failure of Genomatica to reach any milestone,
shall not be a breach of the foregoing so long as such Party uses commercially reasonable efforts to achieve such result, but 

  

					
		  	4	  	***Confidential Treatment Requested

 
Genomatica’s failure to devote the time and efforts of 10 FTEs (as defined and described in Section 6.1 below) to the Program and the Development Plan shall be considered a breach of
this Agreement unless otherwise approved in writing by WMOG. To the extent specified in the Development Plan and otherwise permitted under its existing legal and contractual obligations, each Party will use and disclose its Background Technology
directly relevant to the Program to the other Party. 
 4.2. Condition of Performance by Genomatica. To
the extent Genomatica’s failure to achieve a milestone within the timeline for any Stage is caused by WMOG’s delay in carrying out its responsibilities under the Development Plan, the timeline shall be extended for a period equivalent to
the length of WMOG’s delay. If WMOG’s delay extends more than [...***...] days, or if WMOG is unable to carry out its responsibilities under the Development Plan, the Parties will renegotiate WMOG’s responsibilities under the
Development Plan and the timeline for the applicable Stage. WMOG’s failure to supply syngas for the Program will not be considered a breach of this Agreement by WMOG. 

 

	5.	Exclusivity. 

 Genomatica agrees not to work with any third party [...***...]. WMOG agrees not to work with any third party [...***...]. Nothing herein will prevent a Party from working with its Affiliates.
For clarification, a Party may work with any third party on programs outside the Field, including programs for the production of [...***...] from syngas produced primarily from sources other than Waste materials, for the production of
[...***...] from sources other than syngas, and/or for the production of chemicals other than [...***...] from any source. 
  

	6.	Costs and Success Fees. 

 6.1. Research Costs. WMOG will fund Genomatica’s cost of research for Stages 1-4 over a 4 year period, equivalent to 10 full time equivalents (“FTEs”) annually, up to a total cost of
$14,000,000 (based on $350,000/FTE), with payments to be made as set forth in Exhibit B. 
 6.2. Timing of
Payments. The full Stage cost will accrue the first day of a Stage. However, Stage costs will be paid by WMOG in equal installments as set forth in Exhibit B, with the first installment for each Stage to be paid on the first day of the Stage and
subsequent installments to be paid each [...***...] thereafter, provided, however, the first two (2) installments for Stage 1 shall be made by WMOG no later than [...***...], with the third installment payable [...***...]
thereafter. 
 6.3. Success Payments and Equity Investment. If Genomatica achieves a milestone for a Stage
within the specified timeline for such Stage as set forth in Exhibit B (as may be extended under Section 3.1 or 4.2 or revised under Section 3.2), WMOG will provide the success payment specified for such Stage set forth on Exhibit B
within [...***...] after written notice from Genomatica of achievement of such milestone as provided in Section 3.1. Genomatica will waive the success payments for Stages 1, 2, 3, and 4 if WMOG or an Affiliate invests at least $8.25M
in Genomatica’s Series C1 Preferred Stock Offering (currently anticipated to close in early December, 2010). 

  

					
		  	5	  	***Confidential Treatment Requested

	7.	Ownership. 

7.1. Background Technology. Each Party acknowledges and agrees that, as between the Parties, each Party is and
shall remain the sole and exclusive owner of all right, title, and interest in and to its Background Technology, and that this Agreement does not affect such ownership. Each Party acknowledges that it acquires no rights under this Agreement to the
other Party’s Background Technology other than the limited rights specifically granted in this Agreement and agrees not to practice the other Party’s Background Technology except as expressly permitted in this Agreement or other written
agreement between the Parties. 
 7.2. Ownership of Program Technology. All Program Technology will be
owned by [...***...]. The Parties shall use commercially reasonable efforts to promptly disclose and jointly identify all Program Technology during the term this Agreement. [...***...] except as expressly permitted in this Agreement or
other written agreement between the Parties. 
  

	8.	License Grants. 

 8.1. Program License. Genomatica hereby grants to WMOG a non-exclusive, non-sublicensable (except to WMOG’s Affiliates), royalty free license to use Genomatica’s Background Technology
directly relevant to the Program and Program Technology within the Field and Territory solely for purposes of performing WMOG’s obligations under the Program during the term of this Agreement. WMOG hereby grants to Genomatica a non-exclusive,
non-sublicensable, royalty free license to use WMOG’s Background Technology directly relevant to the Program within the Field and Territory solely for purposes of performing Genomatica’s obligations under the Program during the term of
this Agreement. WMOG reserves all rights under its Background Technology, subject only to the license granted to Genomatica in this Section 8.1, and Genomatica reserves all rights under its Background Technology and the Program Technology,
subject only to the license granted to WMOG in this Section 8.1 and any license granted under a Commercialization Agreement entered into pursuant to Section 8.2. If WMOG grants a sublicense of the license under this Section 8.1 to any
of its Affiliates, WMOG shall cause its Affiliates to comply with all obligations of WMOG hereunder, including, without limitation, Sections 7.2 and 15; provided that WMOG shall at all times be fully responsible for the performance of such
Affiliate. 
 8.2. Commercialization License. Upon achievement of the milestone for Stage 4 within
the timeline for such Stage (as may be extended under Section 3.1 or 4.2, or revised under Section 3.2), WMOG shall have the option to obtain an exclusive license from Genomatica for WMOG and its Affiliates to use the Genomatica Process
Technology within the Field and Territory, subject to the terms of a written commercialization agreement agreed upon by the Parties (the “Commercialization Agreement”). WMOG shall have ninety (90) days from its receipt of notice from
Genomatica of achievement of the Stage 4 milestone to provide Genomatica with written notice of its intent to exercise its option. Upon WMOG’s providing such notice to Genomatica, the Parties will negotiate the terms of the Commercialization

  

					
		  	6	  	***Confidential Treatment Requested

 
Agreement in good faith, according to standard chemical process technology licensing models, including substantially the terms set forth on Exhibit C and such other terms as the parties may
negotiate in good faith. The license will be [...***...]. Notwithstanding the foregoing, if [...***...] then neither Party will have any further obligation to the other Party under this Section 8.2, subject to WMOG’s right to supply Waste
to Genomatica as provided in Section 8.8. 
 8.3. Right of First Offer. 

8.3.1. Outside of the Field. During the term of this Agreement and the periods set forth in this
Section 8.3.1 (each a “Right of First Offer Period”), Genomatica grants to WMOG and its Affiliates the exclusive right of first offer on the following transactions (a “Proposed Transaction”): [...***...]. If this Agreement
is terminated by WMOG before completion of Stage 2, the exclusive right of first offer shall extend [...***...] after such termination. If this Agreement is terminated by WMOG before completion of Stage 4, the exclusive right of first offer shall
extend [...***...] following such termination. If this Agreement is not terminated early, the exclusive right of first offer shall extend [...***...] following expiration of this Agreement. 

8.3.2. Within the Field. If this Agreement [...***...], WMOG and its Affiliates shall have the exclusive right of
first offer in accordance with this Section 8.3 [...***...], WMOG and its Affiliates shall have the exclusive right of first offer [...***...]. 

  

					
		  	7	  	***Confidential Treatment Requested

 8.3.3. Inapplicability. If this Agreement is terminated by
Genomatica, this Section 8.3 and Section 8.4 shall not apply. In no event will the right set forth in this Section 8.3 apply to any sale, transfer or other disposition of all or substantially all of the business or assets of
Genomatica, whether effected by merger, consolidation, sale of stock or assets or otherwise. 
 8.4. Right of
First Offer Procedure. If Genomatica proposes to enter into a Proposed Transaction during the Right of First Offer Period with respect to such Proposed Transaction, it shall first give written notice of such Proposed Transaction to WMOG (the
“First Offer Notice”). The First Offer Notice shall include (A) [...***...], (B) [...***...], and (C) all other material terms and conditions Genomatica deems appropriate, including timelines. Any change to [...***...] will
be considered a new Proposed Transaction, subject to a new First Offer Notice with respect to such Proposed Transaction. [...***...] to enter into the Proposed Transaction with Genomatica, which First Offer shall set forth the terms and conditions
under which WMOG is willing to enter into the Proposed Transaction, including WMOG’s acceptance or rejection of the terms and conditions as set forth in the First Offer Notice and any other commercial terms and conditions proposed or required
by WMOG. Upon receipt of the First Offer within the First Notice Period, Genomatica may accept the First Offer, negotiate the First Offer with WMOG or, after termination of the First Notice Period, solicit additional proposals for a Proposed
Transaction [...***...] and enter into an agreement for such Proposed Transaction with a third party; provided that Genomatica may not enter into an agreement for such Proposed Transaction with a third party unless such agreement is on principal
financial terms that are, in the aggregate, more favorable to Genomatica than those set forth in WMOG’s First Offer. If WMOG does not provide a First Offer within the First Notice Period, Genomatica will be free to enter into a Proposed
Transaction [...***...]. Notwithstanding the foregoing, if Genomatica fails to enter into an agreement for a Proposed Transaction [...***...], Genomatica may not enter into, solicit or negotiate offers for such Proposed Transaction during the Right
of First Offer Period without first complying again in full with the provisions of this Section 8.4, including without limitation, the delivery of a New First Offer Notice to WMOG with respect to the Proposed Transaction. 

8.5. Certain Payments to WMOG Outside of the Field. 

8.5.1. Activities of Genomatica and its Affiliates. If Genomatica or its Affiliates produce and sell commercially
to a third party consumer or distributor [...***...] produced from syngas sourced primarily from coal, natural gas, forestry products or purpose grown crops, Genomatica will pay to WMOG an amount equal to the applicable percentage described below of
Net Sales (as defined below) from Genomatica’s and its Affiliates’ sales of [...***...] produced from syngas sourced primarily from coal, natural gas, forestry products or purpose grown crops using the Program Technology, subject to the
maximum payment set forth in Section 8.5.3, as applicable. Payments will be made to WMOG within sixty (60) days of the end of the calendar quarter in which such Net Sales are made. In no event will Genomatica make any payment to WMOG under
this Section 8.5.1 with respect to the production or commercial sale of [...***...] other than sales by Genomatica and its Affiliates to a third party consumer or distributor of [...***...] produced from syngas sourced primarily from coal,
natural gas, forestry products or purpose grown crops using the Program Technology. For purposes of this Section 8.5.1, the applicable percentage of Net Sales 

  

					
		  	8	  	***Confidential Treatment Requested

 
payable to WMOG shall be as follows: (a) if WMOG terminates this Agreement after commencement of Stage 4 and prior to completion of Stage 4: [...***...]; and (b) if Genomatica achieves
the milestone for Stage 4: [...***...]. 
 8.5.2. Activities of Third Parties. If Genomatica enters into
an agreement, directly or through any Affiliate of Genomatica, that grants to a third party (excluding WMOG or any Affiliate of WMOG or Genomatica) a license or similar right to use the Program Technology to produce for such third party’s or
its affiliate’s use, or for sale commercially to a third party consumer or distributor, [...***...] produced from syngas sourced primarily from coal, natural gas, forestry products or purpose grown crops (“Third Party Commercial
Agreement”), Genomatica will pay to WMOG an amount equal to the applicable percentage described below of Net Profits (as defined below) under such Third Party Commercial Agreement within sixty (60) days of the end of the calendar quarter
in which such Net Profits are received under such Third Party Commercial Agreement. In no event will Genomatica make any payment to WMOG under this Section 8.5.2 with respect to any consideration of any type or kind received by Genomatica or
any of its Affiliates under a Third Party Commercial Agreement that is paid in consideration of any transaction other than the license or similar right to use the Program Technology to produce for such third party’s or its Affiliate’s use,
or for sale commercially to a third party consumer or distributor, [...***...] produced from syngas sourced primarily from coal, natural gas, forestry products or purpose grown crops. For purposes of this Section 8.5.2, the applicable
percentage of Net Profits payable to WMOG shall be as follows: (a) if WMOG terminates this Agreement after commencement of Stage 4 and prior to completion of Stage 4: [...***...]; and (e) if Genomatica achieves the milestone for Stage 4:
[...***...]. 
 8.5.3. Maximum Payment. The maximum total payment under Section 8.5.1 and
Section 8.5.2 shall be equal to [...***...]; provided that no such maximum shall apply if Genomatica achieves the milestone for Stage 4 and the Parties enter into the Commercialization Agreement. 

8.5.4. Inapplicability. If WMOG terminates this Agreement prior to commencement of Stage 4, or this Agreement is
terminated by Genomatica prior to commencement of Stage 4, this Section 8.5 and Sections 8.6 and 8.7 shall not apply. 
 8.6. Calculation of Net Sales and Net Profits. 
 8.6.1.
Net Sales. For purposes of Section 8.5.1, Net Sales shall mean an amount, which shall not be less than zero (0), equal to (a) the total gross amount of sales of [...***...] produced from syngas sourced primarily from [...***...]
using the Program Technology less (b) the sum of (i) trade, quantity and cash discounts actually allowed, (ii) credits or allowances given for rejections or returns, billing errors or retroactive price reductions,
(iii) [...***...], and (iv) [...***...]. 
 8.6.2. Net Profits. For purposes of
Section 8.5.2, Net Profits shall mean any consideration received by Genomatica or any of its Affiliates for the license or similar right to use the Program Technology to produce for the licensee’s or its affiliates’ use, or for sale
commercially to a third party consumer or distributor, [...***...] granted under such Third Party Commercial 

  

					
		  	9	  	***Confidential Treatment Requested

 
Agreement after deducting any investment banking, broker, accounting, tax advisor and legal fees paid by Genomatica or its Affiliates in connection with entering into such Third Party Commercial
Agreement. For clarity, the Parties agree that the following shall not be included in Net Profits: (a) all amounts paid to Genomatica or any of its Affiliates for research and development activities conducted by Genomatica or any of its
Affiliates (including, without limitation, FTE funding and milestone payments tied to research and development) or for the supply of goods or materials by Genomatica or any of its Affiliates, in each case at the cost to Genomatica or its Affiliate
for performing such research and development activities or supplying such goods or materials, and (b) amounts paid for debt or equity securities of Genomatica or its Affiliates to the extent of the fair market value of such debt or equity
securities as determined by the Board of Directors of Genomatica. 
 8.6.3. Form of Consideration. All
non-cash consideration payable by Genomatica to WMOG pursuant to Section 8.5.2 and 8.6.2 shall be paid by Genomatica to WMOG in the same form as the non-cash consideration received by Genomatica or any of its Affiliates in connection with the
Third Party Commercial Agreement and shall be subject to any obligations or restrictions with respect to such non-cash consideration as received by Genomatica or any of its Affiliates. To the extent the form of consideration is legally or
practically unable to be transferred to WMOG, the fair market value of the non-cash consideration received by Genomatica or any of its Affiliates will be used to calculate the amount payable to Genomatica under Sections 8.5.2 and 8.6.2.

 8.7. Audit Rights. Genomatica will keep true and accurate records in connection with the activities
covered by Section 8.5, including, without limitation, all records relating to Genomatica’s computation of Net Sales and Net Profits and the amounts due WMOG under Section 8.5, for at least three (3) years following the period in
which such activities take place. WMOG’s independent auditors will be given access to Genomatica’s relevant records, which will be made available by Genomatica, at no charge to WMOG, at its principal business address during reasonable
business hours upon fourteen (14) days written notice by WMOG, for the purpose of auditing the records and verifying that Genomatica complied with the requirements of Section 8.5. WMOG may only conduct one (1) audit per year. In the
event the audit reveals a discrepancy between the amounts due WMOG and the amounts actually paid by Genomatica, the amount of the discrepancy shall be paid to WMOG within [...***...] following Genomatica’s receipt of the audit report. The audit
shall be conducted at WMOG’s expense, provided, however, if the audit reveals a discrepancy in excess of [...***...] of the amount due WMOG for any one-year period, all out-of-pocket expenses of WMOG (including without limitation fees of its
accountants) in conducting such audit shall be borne by Genomatica. 
 8.8. Right to Supply Feedstock in the
Field in the Territory. In the event that (i) WMOG terminates this Agreement prior to completion of Stage 4, (ii) WMOG does not exercise its option under Section 8.2, (iii) the Parties are unable to reach agreement and enter
into the Commercialization Agreement under Section 8.2 or (iv) the exclusive license under the Commercialization Agreement becomes non-exclusive, then if either (a) Genomatica or its Affiliates produce [...***...] within the Field and
the Territory using the Program Technology or (b) Genomatica enters into an agreement, directly or through any Affiliate of Genomatica, that grants to a third party (excluding WMOG or any Affiliate of WMOG or Genomatica) a license or similar
right to use the Program Technology to produce [...***...] within the Field and Territory (“In-Field Commercial Agreement”), WMOG or its Affiliates will have the right to supply to Genomatica, its Affiliates and any such third party, Waste
material for use as feedstock to produce [...***...] within the Field and the Territory. If this Agreement is terminated by Genomatica, this Section 8.8 shall not apply. Simultaneously with the execution of this Agreement, Genomatica and
WMOG’s Affiliate, Waste Management National Services, Inc. (“WM”), will enter into a Supply Rights Agreement regarding the supply to Genomatica, its Affiliates and third parties to In-Field Commercial Agreements of Waste material for
use as feedstock to produce [...***...] within the Field and Territory. As a condition to Genomatica entering into an In-

  

					
		  	10	  	***Confidential Treatment Requested

 
Field Commercial Agreement, the third party to such agreement must be added as a party to the Supply Rights Agreement, as may be amended with respect to such third party upon mutual agreement of
WM, WMOG and the third party. 
  

	9.	Infringement Impacting Exclusivity. 

 In the event either Party becomes aware of an infringement of Genomatica Process Technology in the Field in the Territory, it will notify the other Party in writing to that effect and shall provide
evidence to support an allegation of infringement. WMOG may request that Genomatica undertake to directly enforce any issued patents included in the Genomatica Process Technology in the Territory against the alleged infringer. If WMOG then holds an
exclusive license under the Commercialization Agreement, and Genomatica does not, in cooperation with WMOG, undertake to pursue such alleged infringement within a reasonable period following notice of alleged infringement, WMOG shall be entitled to
enforce such patents in the name of Genomatica and WMOG as it pertains to such infringement in the Field and in the Territory, at its own expense, and in such case shall be entitled to retain any proceeds from the successful prosecution or
settlement of such action as it pertains to the Field and the Territory. Genomatica shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. Genomatica agrees to be joined as a party in any lawsuit
brought by WMOG under this Section. 
  

	10.	Program Management Responsibilities. 

 Each of the Parties agrees to appoint and keep in place during the term of this Agreement a Program Manager. The Program Managers will (i) be the central point of contact for all matters arising
under this Agreement with respect to the Program; (ii) monitor the progress of and communicate regularly regarding the status of the Program; (iii) review and propose amendments to the Development Plans, as necessary; and
(iv) participate in quarterly meetings to review the overall progress of the Program contemplated hereunder and to provide overall supervision and oversight. The meetings will be held via telephone or in person at alternating locations, as the
Parties shall determine. The Program Managers for the Parties shall be following individuals or their respective designated successors: 
  

			
	 WMOG Program Manager:
	 	Tim Cesarek
		
	 Genomatica Program Manager:
	 	Mark Burk

  

	11.	Escalation and Dispute Resolution 

 11.1. Escalation/Informal Dispute Resolution. Both Parties agree to use all commercially reasonable efforts to work out issues that arise in connection with the performance of this Agreement and
any Development Plan and the negotiations of the Commercialization License. In the event that a dispute arises between the Parties under this Agreement or any Development Plan (each a “Dispute”), the matter shall first be escalated to the
Program Managers in an attempt to settle such Dispute through consultation and negotiation in good faith. If the Program Managers are unable to resolve the Dispute within [...***...], each Party shall appoint an additional senior executive to serve
with the Program Managers as a committee for resolution of the Dispute, which committee shall further attempt to settle such Dispute through consultation and negotiation in good faith. If the above procedures have not resulted in a mutually
acceptable resolution of the issue within [...***...] of the Dispute first being addressed by the Program Managers, either Party may seek resolution of the Dispute through binding arbitration pursuant to Section 11.2 below. 

  

					
		  	11	  	***Confidential Treatment Requested

 11.2. Arbitration. The Parties stipulate and agree that if they are
unable to resolve any Dispute as contemplated by Section 11.1 hereof, then such Dispute shall be resolved by final and binding arbitration conducted in [...***...] by a panel of three (3) arbitrators in accordance with and subject to the
Commercial Arbitration Rules of the American Arbitration Association (“AAA”) then in effect. Following notice of a Party’s election to require arbitration, each Party shall within thirty (30) days select and identify in writing
to the other Party one (1) arbitrator, and those two (2) arbitrators shall within thirty (30) days thereafter select a third arbitrator. If the two arbitrators are unable to agree on a third arbitrator within thirty (30) days,
the AAA shall within thirty (30) days thereafter select such third arbitrator. Discovery as permitted by the Federal Rules of Civil Procedure then in effect shall be allowed in connection with arbitration to the extent consistent with the
purpose of the arbitration and as allowed by the arbitrators. Judgment upon the award rendered in any arbitration may be entered in any court of competent jurisdiction, or application may be made to such court for a judicial acceptance of the award
and an enforcement, as the law of the state having jurisdiction may require or allow. The fact that arbitration is or may be allowed shall not impair the exercise of any termination rights under this Agreement. 

11.3. Exceptions to Arbitration. The only circumstance in which Disputes between the Parties will not be subject to
the provisions of Sections 11.1 and 11.2 above is where a Party makes a good faith determination that a breach of the terms of the Agreement or Development Plan is such that damage resulting from the breach will be so immediate, irreparable, severe,
or otherwise incapable of adequate redress that a temporary restraining order or other immediate injunctive relief is the only adequate remedy for such breach. 
 11.4. Continued Performance. Except where prevented from doing so by the matter in dispute, the Parties agree to continue performing their obligations under this Agreement while any good faith
Dispute is being resolved unless and until such obligations are terminated by the termination or expiration of this Agreement. 
  

	12.	Term of Agreement. 

 12.1. Term and Termination of the Agreement. The term of this Agreement shall commence upon the Effective Date and, unless earlier terminated under Section 3.2 or Section 12.2, which are
the sole grounds for early termination of this Agreement, continue in effect until four (4) years from the Effective Date, provided that if the timeline for completion of any Stage is extended under Section 3.1 or 4.2 or revised under
Section 3.2, the term of this Agreement shall be extended for an equivalent period. 
 12.2. Termination
of the Agreement. This Agreement may be terminated as set forth in Section 3.2 and in the following circumstances: 
 12.2.1. By a Party upon thirty (30) days prior written notice to the other Party if such other Party breaches any material obligation provided hereunder and the breaching Party fails to cure such
breach within such thirty (30) day period following the notice specifying the nature of the default. The right to terminate this Agreement shall be in addition to any other rights or remedies that may be available to the non-breaching Party at
law or equity as a result of such breach. 
 12.2.2. By a Party, without liability, by providing a notice of
termination to the other Party within thirty (30) days of notice of a Change of Control of such other Party, which termination shall be effective upon closing of such Change of Control. For purposes of this

  

					
		  	12	  	***Confidential Treatment Requested

 
Section, a “Change of Control” of a Party occurs upon: (a) the closing of a merger or other business combination or transaction that results in any person, directly or indirectly,
acquiring beneficial ownership of more than 50% of such Party’s then outstanding shares of voting capital stock, excluding any such transaction principally for bona fide equity financing purposes, or (b) the closing of a sale of all or
substantially all of the assets of such Party to a person in one transaction or in a series of related transactions, excluding any transaction described in clause (a) or (b) in which, immediately after the consummation of such transaction,
the holders of voting capital stock of such Party (or such Party’s ultimate parent entity) immediately prior to such transaction beneficially own, directly or indirectly, (including through one or more Affiliates) more than 50% of the
outstanding voting capital stock of the surviving entity (or the parent of such surviving entity) in such transaction. Each Party must give the other no less than thirty (30) days’ prior notice of any Change in Control of such Party.

 12.2.3. By a Party upon written notice to the other Party in the event of the Insolvency of such other Party.
For purposes of this Section only, “Insolvency” of a Party shall exist if a Party: (i) becomes the subject of a voluntary or involuntary bankruptcy, insolvency, reorganization or liquidation proceeding, which proceeding continues
without being dismissed for a period of at least thirty (30) days; (ii) makes an assignment for the benefit of creditors, consents to the appointment of a conservator or receiver or liquidator in any bankruptcy, insolvency or similar
proceeding; or (iii) admits in writing its inability to generally pay debts when due, makes an assignment for the benefit of creditors, or voluntarily suspends its payment obligations. 

12.2.4. By WMOG upon ninety (90) days prior written notice to Genomatica if any claims [...***...] are allowed,
which allowed claim(s) do not recite (i) [...***...] or (ii) another claim limitation, acceptable to WMOG in its reasonable discretion, which would enable the practice of the Program Technology without infringement of the allowed claim(s)
of the [...***...], unless prior to the effective date of such termination, (A) Genomatica has obtained a license to the [...***...] to practice the inventions claimed in the [...***...] in the Field and Territory or (B) Genomatica
replaces or modifies the Program Technology in a manner, acceptable to WMOG in its reasonable discretion, which would enable the practice of the Program Technology without infringement of the allowed claim(s) of the [...***...]. If WMOG terminates
this Agreement pursuant to this Section 12.2.4, it shall not be obligated to pay any milestone achieved on or after the written notice of termination, or to move to the next Stage, unless and until an event described in clause (A) or
(B) occurs prior the effective date of such termination or WMOG otherwise waives such notice of termination in writing. The Parties agree that all communications between the Parties concerning the infringement or non-infringement of a claim in
a [...***...] or patent shall be subject to and protected by a common interest attorney-client privilege. 
  

	13.	Survival of Provisions. 

 The following provisions of this Agreement shall survive termination or expiration of this Agreement: Section 5 (Exclusivity) (only for one year following expiration or termination as provided in
Section 5); Section 7 (Ownership); Section 8.2 (Commercialization License) (unless this Agreement is terminated prior to achievement of the milestone for Stage 4); Sections 8.3 (Right of First Offer) and 8.4 (Right of First Offer
Procedure) (only for the applicable Right of First Offer Period); Sections 8.5 (Certain Payments to WMOG Outside of the Field), 8.6 (Calculation of Net 

  

					
		  	13	  	***Confidential Treatment Requested

 
Sales and Net Profits) and 8.7 (Audit Rights); Section 8.8 (Right to Supply Feedstock in the Field in the Territory) (for the term of the Supply Rights Agreement); Section 11
(Escalation and Dispute Resolution); Section 13 (Survival Provisions); Section 14 (Limitation of Liability and Damages); Section 15 (Confidentiality); Section 16 (Representations and Warranties); and Section 17
(Miscellaneous). 
  

	14.	Limitation of Liability and Damages. 

 IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ITS AFFILIATES FOR ANY SPECIAL OR CONSEQUENTIAL DAMAGES, REGARDLESS OF THE FORM OF ACTION, WHETHER IN CONTRACT, IN TORT INCLUDING NEGLIGENCE, BY
STATUTE OR UNDER ANY QUASI-CONTRACTUAL THEORY OF LIABILITY, EVEN IF A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. The foregoing limitations of liability and damages will not apply and nothing in this Agreement shall affect either
Party’s liability: (i) for any damages caused by the intentional or grossly negligent acts or omissions of such Party; (ii) for breach of any confidentiality obligation specified herein; or (iii) to the extent prohibited by
applicable law. 
  

	15.	Confidentiality. 

 15.1. Nondisclosure. Each Party hereby agrees that during the term of this Agreement and for a period of [...***...] thereafter it shall not commercialize or disclose the other Party’s
Confidential Information to any person or entity, except to its own Personnel having a need to know such Confidential Information for purposes of the Program, provided each Party shall have entered into non-disclosure agreements with its Personnel
having obligations of confidentiality as strict as those herein prior to disclosure to such Personnel. Each Party agrees that it will not use or permit its Personnel to use any Confidential Information for purposes other than in connection with
performance of its duties or exercise of its rights under this Agreement. Each Party shall use at least the same degree of care in safeguarding the other Party’s Confidential Information as it uses in safeguarding its own Confidential
Information, but in no event shall a Party use less than reasonable diligence and care. Notwithstanding the foregoing, (a) each Party may disclose the existence and terms of this Agreement to third parties in connection with due diligence or
similar investigations by such third parties, provided that any such third party is (i) bound to maintain the confidentiality of this Agreement and its terms in a manner consistent with this Section 15 and (ii) prohibited from using
this Agreement or its terms for any purpose beyond the due diligence or similar investigation, and (b) each Party may disclose Confidential Information of the other Party pursuant to a requirement or request of a governmental agency, pursuant
to the rules of any recognized stock exchange or quotation system, or pursuant to a court or administrative subpoena, order or other such legal process or requirement of law; provided, however, that it shall use commercially reasonable efforts to:
(i) first notify the other of such request or requirement, unless such notice is prohibited by statute, rule or court order; (ii) attempt to obtain the other Party’s consent to such disclosure; and (iii) in the event consent is
not given, agree to allow the disclosing Party to file a motion to quash, or take a similar procedural step to frustrate the production or publication of information. Nothing herein shall require either Party to fail to honor a subpoena, court or
administrative order or requirement on a timely basis. Each Party shall cooperate with the other in an effort to limit the nature and scope of any required disclosure of Confidential Information and the Parties shall coordinate with each other with
respect to the timing, form and content of such required disclosure to the extent practicable under the circumstances, provided that, if the Parties are unable to agree on the form or content of any required disclosure, such disclosure shall be

  

					
		  	14	  	***Confidential Treatment Requested

 
limited to the minimum required, as determined by the disclosing Party in consultation with its legal counsel. 

15.2. Return or Destruction of Confidential Information. Upon written demand by the disclosing Party, the receiving
Party shall: (i) cease using the Confidential Information, (ii) return the Confidential Information and all copies, notes or extracts thereof to the disclosing Party within seven (7) days of receipt of demand; and (iii) upon
request of the disclosing Party, certify in writing that the receiving Party has complied with the obligations set forth in this paragraph. 
 15.3. Equitable Remedies. Notwithstanding any arbitration obligations set forth in this Agreement, each Party acknowledges and agrees that the other Party’s remedies at law for breach or
threatened breach of any of the provisions of this Section 15 would be inadequate and, in recognition of that fact, in the event of any such breach or threatened breach, it is agreed that, in addition to other remedies to which it may be
entitled, the other Party will be entitled to equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction without the necessity of posting bond, or any other equitable remedy which may then be
available; provided, that nothing herein contained will be construed as prohibiting the non-breaching Party from pursuing any other remedies available to it for such breach or threatened breach, including recovery of damages from such breaching
Party. 
 15.4. Independent Development and Residuals. The terms of confidentiality under this Agreement
shall not be construed to limit either Party’s right to develop independently or acquire products without use of the other Party’s Confidential Information. The disclosing Party acknowledges that the receiving Party may currently or in the
future be developing information internally, or receiving information from other Parties, that is similar to the Confidential Information. Accordingly, except as provided in this Agreement, neither Party shall be prohibited from developing or having
developed for it products, concepts, systems or techniques that are similar to or compete with the products, concepts, systems or techniques contemplated by or embodied in the Confidential Information provided that the receiving Party does not use
the Confidential Information of the disclosing Party or otherwise violate any of its obligations under this Agreement in connection with such development. Further, subject to the other restrictions and limitations contained in this Agreement, the
residuals resulting from access to or work with such Confidential Information shall not be considered a breach of the confidentiality obligations contained in this Agreement. The term “residuals” means non-specific information in
non-tangible form, which may be retained by persons who have had access to the Confidential Information in accordance with the terms of this Agreement, including general ideas, concepts, know-how or techniques contained therein. Neither Party shall
have any obligation to limit or restrict the assignment of such persons or to pay royalties for any work resulting from the use of residuals. 
 15.5. NDA. The terms of this Section 15 shall supersede the NDA as of the Effective Date of this Agreement. 
  

	16.	Representations and Warranties. 

 16.1. Genomatica’s Representations and Warranties. Genomatica represents and warrants to WMOG as follows: (a) Genomatica owns or possesses the necessary rights, title and licenses
necessary to perform its obligations hereunder or believes it can acquire the foregoing on reasonable terms; and (b) each of its Personnel performing any work under this Agreement will have entered into a written invention assignment agreement
requiring each such individual 

  
 15 

 
to assign to Genomatica all right title and interest in and to any Intellectual Property first conceived of, or reduced to practice by, such individual during the term of their employment or
engagement. 
 16.2. WMOG’s Representations and Warranties. WMOG represents and warrants to
Genomatica as follows: (a) WMOG owns or possesses the necessary rights, title and licenses necessary to perform its obligations hereunder; and (b) each of its Personnel performing any work under this Agreement will have entered into a
written Invention assignment agreement requiring each such individual to assign to WMOG all right title and interest in and to any Intellectual Property first conceived of, or reduced to practice by, such individual during the term of their
employment or engagement. 
 16.3. DISCLAIMER OF WARRANTIES. EXCEPT AS SPECIFICALLY PROVIDED IN THIS
SECTION, EACH PARTY DISCLAIMS ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, TO THE FULLEST EXTENT PERMITTED BY LAW, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE AND NONINFRINGEMENT. NEITHER
PARTY MAKES ANY REPRESENTATION OR WARRANTY WITH REGARD TO THE SUCCESS OF THE PROGRAM OR THE USEFULNESS OF ANY BACKGROUND TECHNOLOGY OR PROGRAM TECHNOLOGY. 
  

	17.	Miscellaneous. 

 17.1. No Third Party Beneficiaries. Unless otherwise expressly provided, no provisions of this Agreement are intended or shall be construed to confer upon or give to any person or entity other than
Genomatica, WMOG and WMOG’s Affiliates any rights, remedies or other benefits under or by reason of this Agreement 
 17.2. Force Majeure. Neither Party shall be responsible for delays in performing or from failing to perform its obligations under this Agreement (other than any obligation to make payments when
due) to the extent the delays or failures result from causes beyond the reasonable control of the Party, and which the Party could not have prevented using commercially reasonable measures, including, but not limited to, acts of God or of the public
enemy, U.S. or foreign governmental actions, labor shortages or strikes, communications or utility interruption or failure, fire, earthquake, flood, epidemic, and freight embargoes. 

17.3. Governing Law. This Agreement shall be construed according to, and the rights of the Parties shall be
governed by, the laws of the State of New York, without reference to its conflict of laws rules. 
 17.4.
Independent Contractor Status. WMOG and Genomatica agree that they shall each perform their duties under this Agreement as an independent contractor. Personnel employed or retained by each Party who perform duties related to this Agreement
shall remain under the supervision, management, and control of such Party. Except as expressly set forth herein, neither Party shall have any right or authority to create any obligation, warranty, representation or responsibility, whether express or
implied, on behalf of the other Party in any manner whatsoever without the expressed written consent of the other Party. Each Party shall be solely responsible for the compensation of all Personnel who perform any activities on their behalf pursuant
to this Agreement or any Development Plan. 

  
 16 

 17.5. Notices. Any written notice or demand required by this
Agreement shall be sent by registered or certified mail, personal delivery, overnight commercial carrier, or facsimile. If hand delivered, the notice will be effective upon delivery. If by facsimile, the notice will be effective when sent. If sent
by overnight carrier, the notice will be effective the day after deposit. If mailed, the notice will be effective five (5) business days after being deposited with the United States Postal Service by certified mail, return receipt requested. In
each case the notice shall be addressed appropriately to the intended recipient, as follows: 
  

					
		 	Genomatica:	  	Genomatica, Inc.
		 		  	10520 Wateridge Circle
		 		  	San Diego, CA 92121
		 		  	Telephone: (858) 824-1771
		 		  	Facsimile: (858) 824-1772
		 		  	Attention: Chief Technology Officer
		 	With a copy to:	  	
		 		  	Cooley LLP
		 		  	4401 Eastgate Mall
		 		  	San Diego, CA 92121-1909
		 		  	Telephone: (858) 550-6013
		 		  	Facsimile: (858) 550-6420
		 		  	Attention: Tom Coll
		 		  	                  Kay Chandler
		 		  	
		 	WMOG:	  	WM Organic Growth, Inc.
		 		  	1001 Fannin St., Suite 4000
		 		  	Houston, TX 77002
		 		  	Telephone: (713) 394-2181
		 		  	Facsimile: (866) 404-9532
		 		  	 Attention: Vice President/Director of
 Business Development

		 		  	 With a copy to General Counsel at the
 same address and at the following
 facsimile number: (713) 209-9710

		 	With a copy to:	  	
		 		  	Stinson Morrison Hecker LLP
		 		  	1201 Walnut, Suite 2900
		 		  	Kansas City, MO 64106
		 		  	Telephone: (816) 842-8600
		 		  	Facsimile: (816) 691-3495
		 		  	Attention: Jack Bowling
		 		  	                  Andrea Sellers

 Any Party may change the address at which it receives notices by giving written notice to the other Party
in the manner prescribed by this Section 17.5. 
 17.6. Entire Agreement. This Agreement sets forth
the entire agreement between the Parties with regard to the subject matter hereof. No other agreements, representations, or 

  
 17 

 
warranties have been made by either Party to the other with respect to the subject matter of this Agreement, except as referenced herein. 

17.7. Assignment. This Agreement shall be binding upon the Parties and their respective successors, representatives
and permitted assigns. Except as set forth herein, neither Party may assign this Agreement or its rights and obligations contained herein, nor may either Party delegate its duties herein, except upon receipt of the other Party’s written
approval, not to be unreasonably withheld or delayed; provided, however, that a Party may, without the other Party’s consent, assign this Agreement or its rights and obligations contained herein, or delegate its duties herein, to (i) a
successor in interest to all or substantially all of the business of such Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise, or (ii) any Affiliate, provided that such third party successor in
interest or Affiliate can reasonably assume all of the obligations of such Party under this Agreement, but nothing in this Section 17.7 restricts the Parties’ right to terminate this Agreement under Section 12.2.2. Notwithstanding the
foregoing, Genomatica may not assign this Agreement or its rights and obligations contained herein, or delegate its duties herein, to a successor in interest or Affiliate that is a competitor of WMOG without WMOG’s written approval, which may
be withheld in WMOG’s discretion., and for purposes of this provision, a competitor of WMOG shall mean an entity that derives at least 60% of its revenue from a combination of one or more of Waste collection, transport, disposal and treatment,
as measured for the most recently completed four (4) fiscal quarters prior to the date of such assignment or delegation by Genomatica. Exemplary competitors, include, but are not limited to Republic Services, Inc. and Waste Connections, Inc.
Any attempted assignment or delegation without the prior written consent required by this Section 17.7 shall be void and ineffective. 
 17.8. Severability. If any of the provisions of this Agreement are found or deemed by a court to be invalid or unenforceable, they shall be enforced to the maximum extent permissible under
applicable law, and shall not cause the invalidity or unenforceability of the remainder of this Agreement. 

17.9. Waiver. Neither Party shall by mere lapse of time without giving notice or taking other action hereunder be
deemed to have waived any breach by the other Party of any of the provisions of this Agreement. The waiver by either Party of a particular breach of this Agreement by the other Party shall not be construed as, or constitute, a continuing waiver of
such breach, or of other breaches of the same or other provisions of this Agreement. 
 17.10. Amendment.
This Agreement and the Development Plans may be amended only by a subsequent written agreement signed by both Parties which specifically identifies itself as a written amendment to this Agreement or a Development Plan. 

17.11. Counterparts. This Agreement may be executed in two (2) or more counterparts and all counterparts so
executed shall for all purposes constitute one agreement, binding on all Parties. Signature pages may be delivered by facsimile or other electronic means. 
 [Remainder of page intentionally left blank] 

  
 18 

 The Parties represent, by the signatures below, that this Agreement has been executed by
their duly authorized representatives to be effective as of the Effective Date. 
  

					
	WM Organic Growth, Inc.	 	Genomatica, Inc.	 	
			
	 By: /s/ illegible
	 	By: /s/ William Baum	 	 
			
	 Title: President
	 	Title: Executive Chairman	 	
			
	 Date:
	 	Date: 12/10/10	 	

 [Signature page for Joint Development Agreement] 

  
 19 

 DEVELOPMENT PLAN 

			
	 SYNGAS TO [...***...]
	  	

		  

  

 EXHIBIT A 

Development Plan 

Waste-Derived Syngas to [...***...] 
 September 2010 
 

 
 Genomatica and Waste Management have outlined a 4-stage program for developing and commercializing a bioprocess for
converting waste-derived syngas to [...***...]. This document details the R&D and engineering tasks, milestones, timelines, and resources necessary to advance this program from the proof-of-concept stage to commercial-scale development.
Specifically, the first three stages of R&D covering [...***...] are aimed at developing a platform microorganism that efficiently utilizes [...***...] syngas for the production of [...***...]. Stages 1-3 of this program encompass: 

    [...***...] 

    [...***...] 

    [...***...] 

    [...***...] 
 Stage 4
involves [...***...]. Stage 4 will entail: 
     [...***...] 

  

					
	 	  	CONFIDENTIAL	  	 
		  	1	  	***Confidential Treatment Requested

 DEVELOPMENT PLAN 

			
	 SYNGAS TO [...***...]
	  	

		  

  

 [...***...] 

  

					
	 	  	CONFIDENTIAL	  	 
		  	2	  	***Confidential Treatment Requested

 DEVELOPMENT PLAN 

			
	 SYNGAS TO [...***...]
	  	

		  

  

 [...***...] 

  

					
	 	  	CONFIDENTIAL	  	 
		  	3	  	***Confidential Treatment Requested

 DEVELOPMENT PLAN 

			
	 SYNGAS TO [...***...]
	  	

		  

  

 The effort will substantially leverage Genomatica’s intellectual property and technology platform
for metabolic engineering, which integrates proprietary best-in-class computational modeling with state-of-the-art experimentation and process engineering. 
 [...***...] 

  

					
	 	  	CONFIDENTIAL	  	 
		  	4	  	***Confidential Treatment Requested

 DEVELOPMENT PLAN 

			
	 SYNGAS TO [...***...]
	  	

		  

  

 [...***...] 
 Stages of Genomatica/Waste Management Syngas Program 
  

					
	 Stage
	  	 Milestone
	  	 Timeline

			
	 [...***...]
	  	[...***...]	  	[...***...]
			
	 [...***...]
	  	[...***...]	  	[...***...]
			
	 [...***...]
	  	[...***...]	  	[...***...]
			
	 [...***...]
	  	[...***...]	  	[...***...]

 This document details the timelines, tasks, and resources required to hit all [...***...] where process design
engineering packages will be completed as a prelude to process scale-up. 
 Stage 1-3 Objectives 

  

					
	 	  	CONFIDENTIAL	  	 
		  	5	  	***Confidential Treatment Requested

 DEVELOPMENT PLAN 

			
	 SYNGAS TO [...***...]
	  	

		  

  

 [...***...] 
 Stage 1-3 Tasks and Timelines 
 Detailed timelines are outlined below for the
[...***...] 

  

					
	 	  	CONFIDENTIAL	  	 
		  	6	  	***Confidential Treatment Requested

 DEVELOPMENT PLAN 

			
	 SYNGAS TO [...***...]
	  	

		  

  

 [...***...] 
 Stage 1-3 Milestones 
 A detailed set of major milestones and program deliverables
are shown in the matrix below, along with projected dates for completion. Major program milestones are highlighted and are linked to the timeline figure shown above. 

  

					
	 	  	CONFIDENTIAL	  	 
		  	7	  	***Confidential Treatment Requested

 [...***...] 
 Stage 1-3 Resources 
 [...***...] 

Stage 4 Objectives: [...***...] 

  

					
		  	8	  	***Confidential Treatment Requested

 [...***...] 
 Stage 4: Tasks, Timelines, and Milestones 
 [...***...] 

  

					
		  	9	  	***Confidential Treatment Requested

 [...***...] 

  

					
		  	10	  	***Confidential Treatment Requested

 [...***...] 

  

					
		  	11	  	***Confidential Treatment Requested

 Stage 4 Resources 
 [...***...]. 
 Intellectual Property 

[...***...] 

  

					
		  	12	  	***Confidential Treatment Requested

 EXHIBIT B 

Program Milestones, Timeline, Stage Costs and Success Payments 

 

									
	 Stage
	  	 Milestone
	  	Timeline(1)	  	Stage Cost	  	Success
Payment
	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  

	(1)	[...***...] is subject to any changes mutually agreed upon in writing by the Parties. 

	(2)	The first month of Stage 1 is intended to allow a ramp-up for hiring of Personnel. 

	(3)	The Stage Costs for each of Stages 1 and 2 will be paid in three equal installments. 

	(4)	The Stage Cost for Stage 3 will be paid in four equal installments. 

	(5)	The Stage Cost for Stage 4 will be paid in six equal installments. 

  

					
		  	1	  	***Confidential Treatment Requested

 EXHIBIT C 

Terms for Inclusion in Commercialization License 
 - Development plans for Stages [...***...] of the Program, including [...***...] 
 -Timing
regarding the [...***...] 
 -Timing regarding [...***...] 
 -Revenue sharing structure for [...***...] 
 -The revenue sharing
structure for [...***...] 
 -Royalties payable to [...***...] 

-The total royalty due for [...***...] 

-The full production cost of a [...***...] 

-An example of the revenue sharing structure, using placeholder values for illustration, is attached at Exhibit D.

 -At the time the revenue sharing structure is negotiated, [...***...] 

  

					
		  	1	  	***Confidential Treatment Requested

 [...***...] 

  

					
		  	2	  	***Confidential Treatment Requested

 EXHIBIT D 

Sample Revenue Sharing Structure 
 [...***...] 

  

					
		  		  	***Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]